Front. Pharmacol. Frontiers in Pharmacology Front. Pharmacol. 1663-9812 Frontiers Media S.A. 961725 10.3389/fphar.2022.961725 Pharmacology Review The crosstalk between sonodynamic therapy and autophagy in cancer Zhang et al. 10.3389/fphar.2022.961725 Zhang Yujie 1 2 Zhao Yuanru 2 Zhang Yuanyuan 2 Liu Qingguang 1 Zhang Mingzhen 1 2 * † Tu Kangsheng 1 2 * † 1 Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China 2 School of Basic Medical Sciences, Xi’an Jiaotong University Health Science Center, Xi’an, Shaanxi, China

Edited by: Bo Liu, Sichuan University, China

Reviewed by: Haiyang Yu, Tianjin University of Traditional Chinese Medicine, China

Xiaoxiao Huang, Shenyang Pharmaceutical University, China

 *Correspondence: Mingzhen Zhang, mzhang21@xjtu.edu.cn; Kangsheng Tu, tks0912@foxmail.com

ORCID: Mingzhen Zhang, orcid.org/0000-0002-4686-6526; Kangsheng Tu, orcid.org/0000-0002-0032-1459

This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Pharmacology

 15 08 2022 2022 13 961725 23 06 2022 08 07 2022 Copyright © 2022 Zhang, Zhao, Zhang, Liu, Zhang and Tu. 2022 Zhang, Zhao, Zhang, Liu, Zhang and Tu

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

As a noninvasive treatment approach for cancer and other diseases, sonodynamic therapy (SDT) has attracted extensive attention due to the deep penetration of ultrasound, good focusing, and selective irradiation sites. However, intrinsic limitations of traditional sonosensitizers hinder the widespread application of SDT. With the development of nanotechnology, nanoparticles as sonosensitizers or as a vehicle to deliver sonosensitizers have been designed and used to target tissues or tumor cells with high specificity and accuracy. Autophagy is a common metabolic alteration in both normal cells and tumor cells. When autophagy happens, a double-membrane autophagosome with sequestrated intracellular components is delivered and fused with lysosomes for degradation. Recycling these cell materials can promote survival under a variety of stress conditions. Numerous studies have revealed that both apoptosis and autophagy occur after SDT. This review summarizes recent progress in autophagy activation by SDT through multiple mechanisms in tumor therapies, drug resistance, and lipid catabolism. A promising tumor therapy, which combines SDT with autophagy inhibition using a nanoparticle delivering system, is presented and investigated.

 sonodynamic therapy (SDT) sonosensitizers autophagy nanoparticles cancer 1 Introduction

Ultrasound (US) has been widely used for both diagnostics and therapeutics in many fields, such as B-scan ultrasonography, bone repair, diabetic nephropathy, cancer therapy, immunotherapy, vaccination, and drug delivery (Cao et al., 2016; Escoffre et al., 2016; McHale et al., 2016; Padilla et al., 2016). Among these applications, the flexibility of US as an approach for noninvasively eradicating target solid tumors has recently drawn increasing attention (McHale et al., 2016). In cancer therapy, an ideal approach would be to apply a harmless stimulus that could lead to cytotoxic events at the target tumor tissue specifically and accurately. SDT, with its deep tissue penetration and high precision, has a great potential to become an ideal tumor therapy since sonochemical or sonophotochemical reactions, which lead to cytotoxicity under a controlled US irradiation with the help of certain chosen sonosensitizers (Liu et al., 2015). The major limitations of the sonosensitizers used in the SDT include poor delivery accuracy and high toxicity (Pelt et al., 2018). With the development of nanotechnology, nanoparticles (NPs)-based sonosensitizers were designed, which made use of NPs to deliver the sonosensitizers to target tissues or tumor cells with high specificity (Chen et al., 2014; Qian et al., 2016; Feng et al., 2019; Qu et al., 2020). The other problem encountered is that SDT can promote autophagy in tumor cells, which influences the efficiency of SDT. In other words, autophagy can assist tumor cell survival by recycling damaged organelles and misfolded proteins under different stress conditions (Helgason et al., 2013; White et al., 2015; Levy et al., 2017). Researchers have proposed to inhibit the SDT-induced autophagy in order to improve the efficiency of SDT improvement (Chen et al., 2014; Mahalingam et al., 2014; Vogl et al., 2014; Song et al., 2018; Feng et al., 2019; Qu et al., 2020).

In this review, the mechanism and sonosensitizers of SDT are firstly summarized. Next, the recent progress in tumor therapies with emphasis on SDT is introduced. The relationship between SDT and autophagy in tumor therapies and other metabolic pathways is also reviewed. To better present this study, an introduction to autophagy is also detailed. Finally, a promising tumor therapy, which combines SDT with autophagy inhibition using a nanoparticle delivering system, is presented and investigated.

 2 Sonodynamic therapy

Before the use of US for therapeutic purposes, the application of light was considered an option for non-invasive therapy, which was referred to as photodynamic therapy (PDT). PDT is the predecessor of SDT. PDT involves three constituent elements: a light source, a photosensitizer, and the local tissue oxygen. Reactive oxygen species (ROS) are formed in the tumor cells and tissues with porphyrins upon irradiation with light (Rkein and Ozog, 2014). PDT can interfere with cytokine-mediated responses in tumor progression and metastasis and play a pivot role (Kaleta-Richter et al., 2019). However, since the light has only a limited penetration depth, PDT cannot be effectively applied to deep-seated tumors (Huang, 2005). At the same time, PDT highly relies on the ability of specific photosensitizing agents to concentrate in tumor cells (Kessel and Oleinick, 2009). Therefore, lacking a suitable photosensitizing agent with high efficiency, good sensitivity, wide applicability, and low toxicity severely constrain the research on PDT. In addition, the study showed that autophagy induced by PDT treatment could act as a mode of cell death after PDT (Buytaert et al., 2006; Kessel et al., 2006; Xue et al., 2007; Buytaert et al., 2008). However as a double-edged sword, autophagy can also promote tumor cell survival by compartmentalizing and recycling damaged tumor cell components after PDT, which significantly reduces the sensitivity and efficiency of PDT (Kessel et al., 2006; Kessel and Oleinick, 2009; Kaleta-Richter et al., 2019).

Based on PDT, SDT is gradually developed and optimized. The SDT is a new non-invasive tumor treatment method raised by Yumita et al. (1989) in 1989. When conducting research on PDT, they observed that some hematoporphyrin derivatives could also induce cell death under US irradiation (Yumita et al., 1989). It was then found that combined with US irradiation, some hematoporphyrin derivatives could act as sonosensitizers for tumor therapy, and this therapy was referred to as SDT. Research shows that most photosensitizers are sonosensitizers. Both PDT and SDT require the use of photosensitizer/sonosensitizers to trigger intracellular oxygen generation ROS to kill tumor cells. The SDT relies on the US and sonosensitizers present in the tumor tissue, with specific frequency and intensity, US irradiates the tumor site in deep tissue for a particular time, a lethal sono-damage such as necrosis and cell apoptosis by both mechanical stress and chemical reactions is caused and finally kills the tumor cells with high specificity and accuracy (Wang et al., 2013b; Parzych and Klionsky, 2014). Due to the deep penetration of US, SDT overcomes the major limitation of PDT. The SDT method is superior to the PDT method with deeper tissue penetration, higher precision, fewer side effects, and better patient compliance (Wang et al., 2013b; Pan et al., 2018b). The cytotoxic mechanisms of SDT in tumor treatment mainly include ultrasonic cavitation effect, singlet oxygen mechanism, mechanical damages, ultrasonic heating effect, apoptosis theory, and comprehensive effects of the mentioned mechanisms (Liu et al., 2015; Rengeng et al., 2017).

The major limitations of the sonosensitizers used in the SDT include poor delivery accuracy and high toxicity (Pelt et al., 2018). With the development of nanotechnology, nanoparticle-based sonosensitizers were designed, which make use of NPs to deliver the sonosensitizers to target tissues with high specificity (Chen et al., 2014; Qian et al., 2016; Feng et al., 2019; Qu et al., 2020). The other problem encountered is that SDT can promote autophagy in tumor cells, which inhibits the efficiency of SDT. It is because autophagy can assist tumor cell survival by recycling damaged organelles and misfolded proteins under different stress conditions (Helgason et al., 2013; White et al., 2015; Levy et al., 2017). Recently, the effect of autophagy induced by SDT in tumor treatment has drawn increasing attention (Wang et al., 2013b). Researchers have proposed to inhibit the SDT-induced autophagy in order to improve the efficiency of SDT (Chen et al., 2014; Mahalingam et al., 2014; Vogl et al., 2014; Song et al., 2018; Feng et al., 2019; Qu et al., 2020).

2.1 Mechanism of sonodynamic therapy

The mechanisms of SDT include the generation of ROS, US mechanical damage, and thermal destruction. Figure 1 depicts the possible mechanisms of SDT.

Schematic illustration of possible mechanisms of SDT. Ultrasound irradiation activates sonosensitizer from a ground state to an excited state to form cavitation around the surface of cancer cells. The energy from the collapse of cavitating bubbles can initiate sonoluminescent light, mechanical damage, and thermal damage to cancer cells. The energy can be transferred to the circumambient oxygen to produce a large amount of ROS, including singlet oxygen, peroxide, and hydroxyl radical, which subsequently mediate cell apoptosis and necrosis. At the same time, the cavitation also causes shock waves, shear stress, and hyperthermia to induce cell death.

 2.1.1 Generation of reactive oxygen species

ROS generation is the most widely accepted mechanism of SDT, and this theory focuses on the cancer cell apoptosis caused by ROS production induced by cavitation and sonosensitizers (Nora Frulio et al., 2010). Under the irradiation of US, sonosensitizers can be activated from the ground state to the excited state to generate ROS, including singlet oxygen and hydroxyl radicals. Acoustic cavitation plays an important role in activating sonosensitizers to generate ROS during the interaction of US with an aqueous environment. The cavitation process involves the nucleation, growth, and implosive collapse of gas-filled bubbles under certain US conditions. Cavitation can be classified into stable cavitation and inertial cavitation based on its nature. In stable cavitation, gas-filled bubbles oscillate with the surrounding liquid to create a mixing of the surrounding media. In inertial cavitation, the gas-filled bubbles grow to a near resonance size and expand before collapsing violently (Suslick, 1990). A considerable amount of energy is released in the implosion, leading to very high temperature (up to 10,000 K) and pressure (up to 81 MPa) in the microenvironment (Cavalli et al., 2018). The resultant extreme temperature and pressure may act as sonochemical reactors and lead to tumor cell necrosis (Misik and Riesz, 2000).

Two kinds of ROS can be generated by different reactions. The sonosensitizers at excited state can react directly with adjacent oxygen to turn hydrogen atoms to free radicals. Alternatively, the energy released by the sonosensitizers from the excited state to the ground state can be absorbed by the adjacent oxygen to produce high active singlet oxygens (1O2), which account for the primary SDT toxicity. In addition, sonoluminescence, a phenomenon referring to that light is generated when a solution is irradiated with US, is identified as another significant mechanism in generating ROS (Suslick et al., 1990; Yin et al., 2016). The sonoluminescent light can motivate the energy-matching photoactive sonosensitizers to a short-lived singlet state, which would lead to photochemical reactions (Didenko et al., 2000; Yin et al., 2016). Pyrolysis can be another possible mechanism for generating ROS (Danno et al., 2008). The extreme temperature and pressure during the implosion of gas-filled bubbles could generate free radicals in the following two ways: direct sonosensitizer breakdown or sonosensitizer reactions with H+ or OH− produced by the thermolysis of water (Danno et al., 2008). Irreversible damage to targeted tumor cells, including cell membrane damage, DNA fragmentation, and mitochondrial membrane potential disturbance, can be induced by the high concentration of ROS (Kwon et al., 2019). Studies have shown that ROS activate autophagy through a variety of pathways to mediate cell survival or death. Especially, it was found that ROS induced by SDT triggered autophagy in a mitochondria-dependent minner (Qu et al., 2020).

 2.1.2 Ultrasound mechanical damages

The main factors causing US mechanical damage are cavitation effects and US radiation force (Yuan et al., 2015). It was reported that the mechanical pressure from US could lead to cell necrosis (Wang et al., 2003; Hiraoka et al., 2006). During the rapid collapsing of gas-filled bubbles under US irradiation, a considerable amount of energy is released to produce extreme temperature and pressure (Hiraoka et al., 2006). High shear stress and strong shock waves are generated, and they enhance the physical damage to cytomembranes, which ultimately lead to mechanical damage and tumor cell necrosis (Forbes et al., 2011).

 2.1.3 Thermal destruction

The increase of tissue temperature through absorption and transformation of the US mechanical energy can also lead to tumor cell necrosis (Xiong et al., 2020). For example, under the irradiation of appropriate US, the sonosensitizer mesoporous silica NPs can cause hyperthermia to kill tumor cells. Due to the high penetration and high energy concentration capabilities of US, SDT can cause thermal destruction to deep-seated tumors (Xiong et al., 2020).

 2.2 Sonosensitizers with nanoparticle delivery system

In SDT, the sonosensitizers can be classified into two groups: organic and inorganic (Table 1). The organic sonosensitizers have high SDT efficiency but with poor pharmacokinetics, skin sensitivity, low stability, and poor SDT efficiency. The inorganic sonosensitizers have superior physical and chemical properties and can be multifunctional. However, the poor SDT efficiency and potential biosafety problems are the main challenges for inorganic sonosensitizers (Liang et al., 2020a).

Summary of sonosensitizers and SDT conditions.

Sonosensitizer Inorganic/organic Biological model US parameters Biological effects References
5-ALA Organic C6 glioma cells in rat 1.0 MHz, 10.0 W/cm2, 5 min Deep seated intracranial glioma tumor size decreased; selective anti-tumour effect Ohmura et al. (2011)
ATX-70 Organic Mammary tumor cells (DMBA) in Sprague–Dawley rat 1.92 MHz, 1.0–5.0 W/cm2, 15 min Significant tumor growth inhibition; strong synergistic effect (Ohmura et al., 2011) Yumita et al. (2007)
DCPH-P-Na(I) Organic MKN-45 cells in mice 1.0 MHz, 1.0 W/cm2, 10 min Potent sonotoxicity on tumor cells under US irradiation; significant tumor growth inhibition; potential for clinical treatment of cancers located deep in the human body without inducing skin sensitivity Hachimine et al. (2007)
Porfimer sodium Organic Mammary tumor cells (DMBA) in Sprague–Dawley rat 1.92 MHz, 1.0–5.0 W/cm2, 15 min Significant tumor growth inhibition; US intensity showed a relatively sharp threshold for the synergistic antitumor effect Yumita et al. (2004)
Hematoporphyrin Organic Hepatoma-22 cells in mice 1.43 MHz, 2.0 W/cm2, 1 min Strong cytotoxic effects; significant lipid peroxidation in tumor cells; tumor volume and weight were remarkably decreased; tumor cell ultra-structure was significantly damaged Wang et al. (2011)
SF1 Organic S180 sarcoma cells in mice 1.0 MHz, 1.2 W/cm2, 3 min Tumor growth inhibition effect was enhanced with increasing US intensity; coagulated necrosis or metamorphic tissue with inflammatory reactions Xiaohuai et al. (2008)
Hematoporphyrin derivatives Organic S180 sarcoma cells in mice 1.1 MHz, 1.5 W/cm2, 3 min SDT induced morphologic changes; important factors inhibiting the tumor cell growth and even inducing tumor cell death: damage of cell structure, change of cytochrome C oxidase activity, degradation and missing of DNA Liu et al. (2003)
Sinoporphyrin sodium Organic 4T1 mouse xenograft model 1.0 MHz, 1.0 W/cm2, 2 min Increased intracellular ROS production; change of membrane permeability; tumor growth and metastatic spreading inhibitions Liu et al. (2016)
Protoporphyrin IX Organic Oral squamous carcinoma in mice 1.0 MHz, 0.89 W/cm2, 20% duty cycle, 15 min Cell cycle arrested at G2/M phase; activate Fas-mediated membrane receptor pathway (regulated by p53) to induce apoptosis Lv et al. (2017)
Chlorin e6 (Ce6) Organic Human breast cancer MDA-MB-231 cells in vitro 1.0 MHz, 0.5–2.0 W/cm2, 1 min Inhibition on the proliferation of cancer cells; dose-dependently Gao et al. (2010)
Rose bengal (RB) Organic Human colorectal adenocarcinoma cell line (HT-29 cells) in mice 1.0 MHz, 1.0 W/cm2, 2 min Suitable for detecting tumor location and size; higher drug accumulation at the tumor site; enhanced ROS generation efficiency; enhanced SDT therapeutic efficacy with minimal side effects Hou et al. (2020)
TiO2 Inorganic C32 melanoma cells in mice 1.0 MHz, 1.0 W/cm2, 2 min Tumor cell viability was significantly decreased; significant inhibition of tumor growth Harada et al. (2011)
PMCS Inorganic Human breast cancer cells in vitro 1.0 MHz, 2.5 W/cm2, 50% duty cycle, 5 min High sonosensitization efficacy and good stability; high ROS production and induced cellular destruction; high tumor inhibition efficiency Pan et al. (2018a)
PtCu3 Inorganic 4T1 breast cancer cells in mice 35 kHz, 3.0 W/cm2, 10 min Highly efficient ROS generation in SDT; significantly enhanced sonotoxicity to cancer cells; minimal toxicity to normal tissues at therapeutic doses Zhong et al. (2020)
BaTiO3 Inorganic In vitro cellular level evaluation and in vivo tumor xenograft assessment 1.0 MHz, 1.0 W/cm2, 50% duty cycle, 1 min Built-in electric field catalyzed the generation of ROS; US triggered cytotoxicity promoted tumor eradication; high therapeutic biosafety. Zhu et al. (2020a)
Porous silicon NPs Inorganic Lung Lewis carcinoma in mice 1.0 MHz, 1.0 W/cm2, 3 min Inhibition on the growth of primary tumor site; slowed down the metastasis process. Sviridov et al. (2017)
Copper-cysteamine Organic 4T1 breast cancer cells in mice 1.0 MHz, 2.0 W/cm2, 3 min Efficient production of ROS; significant inhibition of tumor growth; enhanced cavitation for tumor destruction Wang et al. (2018)
Double-layer hollow manganese silicate (DHMS) Inorganic 4T1 breast cancer cells in mice 1.0 MHz, 1.0 W/cm2, 50% duty cycle, 1 min Highly effective ROS yield; production of oxygen in the tumor micro-environment to overcome the hypoxia of the solid tumor; good tumor inhibition ability and biosafety Pan et al. (2020)

Currently, there are many limitations of sonosensitizers, which significantly influence the efficiency and sensitivity of SDT. The major challenges are the low drug delivery efficiency and limited generation of ROS (Hou et al., 2020). To make SDT practically applicable, thanks to the fast developing nanotechnology, nanoparticles-based sonosensitizers are introduced, which make use of nanoparticles to deliver the sonosensitizers to target tissues or tumor cells with high specificity and accuracy, and in the end, improve the outcomes of SDT (Pan et al., 2018b). Nano-sonosensitizers can be divided into two groups: nanoparticle as intrinsic sonosensitizer (TiO2, Ag/Pt, Si NPs, and polyhydroxy fullerene) and nanoparticle-assisted sonosensitizer (self-assembled, conjugated, embedded, or encapsulated) (Harada et al., 2011; Pan et al., 2018b; An et al., 2020a). Nano-sonosensitizers were summarized in Table 2 of Plenty of previous research has been conducted on NP-mediated SDT. As a typical semiconductor, TiO2 has drawn much attention, and TiO2 NPs are shown to have positive anti-tumor effects both in vitro and in vivo under US irradiation (Harada et al., 2011). Harada et al. (2011) reported that compared to 1 MHz of US irradiation alone, combined US irradiation of mice injected with TiO2 had a significant anti-tumor effect. However, the bio-distributions of traditional TiO2 NPs are hard to manipulate, and the acute and long-run toxicity is unsatisfactory (Chen et al., 2014). Therefore, searching for an efficient and sensitive sonosensitizer is urgently needed.

Summary of nano-sonosensitizers.

NP Drug carried/combination drug Biological models Target cells Biological effects References
TiO2 None C32 melanoma solid tumors in mice C32 melanoma cells Tumor cell viability significantly decreased; remarkable antitumor effect Harada et al. (2011)
Fe3O4 magnetic Chitosan chloride (HTCC)/alginate Gastric SGC7901/ADR tumor bearing mice SGC7901/ADR gastric cancer cells Excessive ROS accumulation and mitochondrial dysfunction; inhibition on the gastric tumor growth; reduced tumor volume Li et al. (2016c)
Silver Reduced graphene-oxide Human cervical cancer (Hela CCL2) cell lines Cervical cancer hela cells Significant effects on the expressions of apoptotic and autophagy genes; accumulation of autophagosomes and autophagolysosomes; substantial generation of ROS Yuan and Gurunathan (2017)
Gold Protoporphyrin IX (PpIX) Colon carcinoma tumor in male BALB/c mice CT26 cancer cells Higher tumor cell cellular uptake of PpIX; significant synergistic inhibitory effect on tumor growth; reduced tumor relative volume; increased average animal survival fraction Shanei et al. (2012)
Porous silicon Dextran (biopolymer) Human lung cancer Hep2 cell lines Hep2 cancer cells Efficient uptake of the NPs by cancer cells; low cytotoxicity at high concentrations; the number of living cancer cells decreased Sviridov et al. (2017)
Hollow polydopamine Platinum NP, doxorubicin (DOX) and chlorine e6 (Ce6) 4T1 breast cancer cells in female Balb/C mice 4T1 cancer cells Excellent biocompatibility with no toxicity to mice; effective delivery of drugs to target tumor cell mitochondria; relieved hypoxic state of the tumor site An et al. (2020a)
Poly-methyl methacrylate Meso-tetrakis (4-sulfonatophenyl) porphyrin (TPPS) Human neuroblastoma SH-SY5Y cell lines SH-SY5Y cells Significant decrease in cancer cell proliferation; significant increase in necrotic and apoptotic cells; increased ROS production Canaparo et al. (2013)
Poly (lactic-co-glycolic acid) (PLGA) methylene blue (MB) and gadodiamide (Gd-DTPA-BMA) MDA-MB-231 breast cancer cells in BALB/c nude mice MDA-MB-231 cells Combined therapeutic and diagnostic functionalities; better enrichment at the tumor site; promoted apoptosis triggered by US; good drug safety Li et al. (2019)
Melanin Folate and hematoporphyrin monomethyl ether Human breast cancer MDA-MB-231 cells in female BALB/c nude mice MDA-MB-231 cells Enhanced photoacoustic imaging-guided SDT; accurate delivery of drugs to the tumor sites; engendered ROS-mediated cytotoxicity towards tumors Huang et al. (2018)
Mesoporous silica Doxorubicin (DOX) and Chlorin e6 (Ce6) Breast cancer MDA-MB-2231 cells in female BALB/c nude mice MDA-MB-2231 cells High drug loading and delivery efficiency; targeted delivery and controllable activation potential; significant antitumor effect Xu et al. (2020b)
Angiopep-2 peptide-modified liposomes Ce6 and HCQ GL261 glioma cells in female C57BL/6 mice GL261 glioma cells Selectively accumulated in the brain tumors during blood brain barrier opening; inhibited tumor growth and prolonged survival time Qu et al. (2020)
Hollow mesoporous TiO2 HCQ and cancer cell membrane coating Human breast cancer MCF-7 cells in nude mice MCF-7 cells Hide from macrophage phagocytosis; recognize and target the tumors by homologous targeting ability; elevated sensitivity of cancer cells to SDT Feng et al. (2019)
Hollow mesoporous manganese trioxide (Mn2O3) hyaluronic acid (HA) and HCQ 4T1 breast cancer cells in female BALB/c mice 4T1 cells Significant lysosomal deacidification and autophagy blockade effects; selectively deliver HCQ to tumor sites; effective HCQ accumulation level at the target site Zhang et al. (2019a)

Organic NP carriers for sonosensitizers are superior in high aqueous solubility, good bio-compatibility, satisfactory targeting specificity, and easy bio-degradation (Qian et al., 2016). Chen et al. (2017b) applied mitochondria targeting liposomes to carry hydrophobic sonosensitizer of hematoporphyrin monomethyl ether, which were released from the liposomes under US, and remarkably prevented the aggregation of sonosensitizers. Canaparo et al. (2013) reported that NPs delivered the sonosensitizers with high accuracy and enhanced the efficiency of carried sonosensitizers. Rui et al. (Hou et al., 2020) designed a sonosensitizer drug delivery system for rose bengal microbubbles. This drug delivery system was shown to have high drug loading content and good US imaging properties. Under US irradiation, the locations and sizes of the tumors were observed. More importantly, the rose bengal microbubbles were converted into rose bengal NPs through sonoporation effects in situ with US irradiation, which could bring many favorable effects, including high drug accumulation, and promoted generation efficiency of ROS. The high drug accumulation at the tumor site reduced the side effects, and the improved SDT efficiency showed great potential for cancer therapies.

The multifunctional NP systems with diagnostic and therapeutic functions have recently gained increasing attention in precision nanomedicine (Huang et al., 2018; Li et al., 2019). In the NP system investigated by Li et al. (2016a), the hydrophilic biodegradable polymeric NPs carried both sonosensitizer and a magnetic resonance contrast agent (Li et al., 2019). In order to target the tumor tissues with higher specificity and accuracy, the tumor-homing and penetrating peptide-F3 was used to decorate the surfaces of NPs. This designed F3 decorated poly lactic-co-glycolic acid NP showed a significantly higher tumor tissue concentration than non-targeted NP. More importantly, under satisfactory drug safety, the apoptosis caused by SDT with the designed multifunctional NP system was promoted. The results indicated a potential for further investigations and even clinical trials.

Huang et al (2018) carried out investigations on the combination of SDT with NP-assisted sonosensitizers under the guidance of photoacoustic imaging, and this novel therapy was expected to eradicate tumor cells accurately. The designed NP-assisted sonosensitizer had a core-shell structure and was based on poly lactic-co-glycolic acid. The core was constructed by integrating melanin NPs for photoacoustic imaging, and the hematoporphyrin monomethyl ether was used to build the shell to enhance photoacoustic imaging-guided SDT. Finally, tumor-targeting ligand folate was attached. The designed NP-assisted sonosensitizer had the following functions: high photoacoustic imaging contrast enhancement capability, accurate delivery of melanin NPs to target tumor tissues, and enhanced SDT performance. Both in vitro and in vivo experiments demonstrated the selective cytotoxicity effects of ROS induced by SDT on tumor cells with the assistance of NP-assisted sonosensitizer, which can promote the eradication of tumor tissues. Meanwhile, the toxicity of the designed NP-assisted sonosensitizer was evaluated, and this sonosensitizer was found to possess high biosafety.

Xu et al. (2020b) synthesized mesoporous silica NPs, and the NPs were loaded with doxorubicin and chlorin e6 as the sonosensitizer. Both in vitro and in vivo experiments were conducted to evaluate the anti-tumor effect of this NP-assisted sonosensitizer under SDT. The NPs were in the shapes of spheres with uniform sizes. The mesoporous structure led to high drug loading and delivery efficiency. On xenograft tumor-bearing mice, under US irradiation, the synthesized NP-assisted sonosensitizer showed a higher tumor suppression effect than doxorubicin combined with chlorin e6 or doxorubicin alone. The results suggested a potential for solid tumor therapy.

Zhang et al. (2019b) designed a mitochondria-targeted and US-activated NP delivery system for enhanced deep-penetration SDT. The built sonosensitizer IR780-based NPs showed effective surface-to-core diffusion in vitro and in vivo. With the guidance of US, the acoustic droplet vaporization effect significantly assisted the conveyance of IR780-NPs from the circulatory system to tumor tissues, and the acoustic wave force increased the penetration depth at the same time. Furthermore, the mitochondrial targeting capability of IR780-NPs improved the delivery accuracy. Following the mitochondrial targeting, the overproduction of ROS rendered cancer cells more susceptible to ROS-induced apoptosis. Meanwhile, IR780-NPs helped with photoacoustic and fluorescence imaging, which provided SDT guidance and monitoring potential.

 2.3 Sonodynamic therapy combined with other therapy

Because of the advantages of SDT, it is an effective method for the treatment of a variety of diseases. Due to the complicated tumor microenvironment, many researchers have integrated SDT with other cancer treatment methods to achieve tumor eradication more effectively (Wan et al., 2016b). SDT can be applied as an adjunctive method to either chemotherapy, PDT, hyperthermotherapy, gas therapy, chemodynamic therapy, immunotherapy, or other therapies (Table 3) (Wan et al., 2016b; Liang et al., 2020a). Recent research suggested that favorable synergistic effects against tumor development and metastasis were achieved in vitro and in vivo when SDT was combined with other tumor therapies (Kondo and Kano, 1987; Gao et al., 2010; Wang et al., 2015b; Liang et al., 2020a).

Category of combination therapy based on SDT in recent years.

Therapy Materials Sonosensitizers In vitro In vivo US parameters References
SDT/chemotherapy Fe3O4–NaYF4@TiO2 TiO2 MCF-7 S180 1 W/cm2 at different time durations (0, 0.5, 1, 3, and 5 min) Song Shen et al. (2014)
Fe3O4@TiO2-doxorubicin TiO2 MCF-7 S180 1 W/cm2; 3 min Shen et al. (2015)
MTN@DTX-CD TiO2 MCF-7 S180 1 W/cm2; 40 s Shi et al. (2015)
HPDF nanomicelle Hematoporphyrin MCF-7, MCF-7/ADR — 1 MHz, 1.5 W/cm2; 30 s Wan et al. (2016a)
HPDF nanoparticles Hematoporphyrin HepG2 HepG2 1.0 MHz, 1.5 W/cm2, 30 s Liu et al. (2017)
DOX@MSN-HA MSN MDA-MB-231 MDA-MB-231 30 s, 6 times of 5 s sonication, sonication interval = 1 min Ding et al. (2017)
O2MB-Gem Rose Bengal MIA PaCa-2, PANC-1 KPC mouse model 1 MHz, 30 s, 3 W/cm2, duty cycle = 50%, and PRF = 100 Hz Nesbitt et al. (2018)
DOX@HMONs-PpIX-RGD PpIX HCC HCC 1.0 MHz, 50% duty cycle; 1 min Li et al. (2018)
DTX/X-NPs Ce6 B16F10 B16F10 1.0 W/cm2 for 1, 3 and 5 min Liu et al. (2018)
HPCID (ICG@PCH@Dox@HA) ICG 4T1 4T1 1.2 MHz for 60 s at 1, 2, and 3 W, Wu et al. (2019)
CDP@HP-T Ce6 4T1 4T1 1.0 W/cm2; 3 min An et al. (2020a)
HPT–DOX TiO2 4T1 4T1 1.0 MHz, 50% duty cycle, 0.5 W/cm2, 2 min Liang et al. (2020b)
O2MB-PTX-DOX and O2MB-PTX-RB Rose Bengal MCF-7 MCF-7 1 MHz, 30 s, 3 W/cm2, duty cycle = 50%, and PRF = 100 Hz Logan et al. (2019)
DOX@FeCPs HMME 4T1, CT26 CT26 1.75 W/cm2 at different time durations (0, 0.5, 1, 3, and 5 min) Xu et al. (2020a)
MSN-DOX-Ce6 Ce6 MDA-MB-231 MDA-MB-231 0.5 W/cm2; 1 min Xu et al. (2020b)
CLH-5-ALA 5-ALA 4T1 4T1-luc cells 1 MHz, 3 W/cm2; 3 min Xiao et al. (2021)
GMCDS-FA@CMC (Au@mSiO2/Ce6/DOX/SLB-FA@CMC) Ce6 3T3, C26 orthotopic colorectal tumors — Zhang et al. (2021c)
CPDP (Ce6/PFP/DTX/PLGA) Ce6 4T1 4T1 1–2 W/cm2 for different duration times Zhang et al. (2021b)
PCNP-DTX Phycocyanin (PC) MCF-7 S180 1 MHz, 0.75 W/cm; 2 min Cao et al. (2021)
DOX@PCN-224/Pt TCPP HUVEC, SKOV3 and CT26 CT26 1.0 MHz, 1.75 W/cm−2; 5 min Ren et al. (2022)
ZTC@M(ZIF-8@TPZ/Ce6@cytomembrane) Ce6 AGS AGS 1.0 MHz, 1.5 W/cm2; 3 min Yu et al. (2022)
SDT/immunotherapy MFC (membrane-coated Fe-PDAP/Ce6) Ce6 4T1 4T1 1.0 MHz, 2 W/cm2, 50% duty cycle; 1 min Jiang et al. (2022)
PFCE@THPPpf-COPs THPP CT26 CT26 40 kHz, 2 W; 10 min Yang et al. (2022)
PEG-CDM-aPD-L1/Ce6 Ce6 B16–F10 B16–F10 2 MHz, 2.0 W/cm2, 20% duty cycle; 5 min Huang et al. (2021)
TiO2-Ce6-CpG TiO2-Ce6-CpG Hepa1-6 Hepa1-6 1.0 MHz, duty cycle: 50%, 1.0 W/cm2; 4 min Lin et al. (2021)
TIR@FITC-Nrf2-siRNA IR780 CT26 CT26 1 MHz, 1.0 W/cm2, 50% duty cycle; 10 min Wan et al. (2021)
SDT/PTT/Immunotherapy CHINPs HMME 4T1 4T1 1 MHz, 2.0 W/cm2, 50% duty cycle for different durations Lin et al. (2022)
SDT-PDT UCNPs@SiO2-RB HMME T24 — 2 W/cm2; 10 min Xu et al. (2017)
Fe@UCNP-HMME HMME T24 — 2 W/cm2; 5 min Wang et al. (2019)
UCNP@mSiO2(RB)-AgNPs Rose Bengal (RB) MRSA — 2 W/cm2; 5 min Zhao et al. (2020)
TiO2 TiO2 PC3 — — Aksel et al. (2021)
NSGQDs Doped graphene quantum dots MCF7 — 1 MHz, 1 W/cm2 Nene and Nyokong, (2021)
SDT/gas therapy HMME/MCC-HA HMME MCF-7, NIH3T3 MCF-7 1 MHz, 1 W/cm2: 1 min Feng et al. (2018)
Lip-AIPH Bubble liposomal systems MCF-7 MCF-7 1.0 MHz, 2 min, 50% duty cycle Lin et al. (2019)
GCZ@M (GSNO/Ce6@ZIF-8@Mem) Ce6 4T1 4T1 1 W/cm2; 3 min An et al. (2020b)
Au NR-mSiO2/AIPH Au NR-mSiO2/AIPH MCF-7 MCF-7 1.0 MHz, 0, 1.0, 1.5, 2.0, 2.5 W/cm2, duration (0, 3, 5, 7, 10 min) Ye et al. (2021)
OCN-PEG-(Ce6-Gd 3 +)/BNN6 Ce6 4T1 4T1 1 W/cm2, duty cycle = 50%, pulse frequency = 100 Hz, and frequency = 1 MHz; 5 min Zheng et al. (2021b)
Re-Cy/Re-CHO Re(I) tricarbonyl complexes 4T1 4T1 0.3 W/cm2, 3 MHz; 15 min Zhu et al. (2022)
T-mTNPs@L-Arg TiO2 MCF-7 MCF-7 1 MHz, 1 W/cm2; 1 min Zuo et al. (2022)
BPPL (BP-Pt-PEI-L-Arg) Black phosphorus 4T1 4T1v 1.0 MHz, 50% duty cycle, 1.5 W/cm2; 3 min Cheng et al. (2022)
SDT/PTT HMNCs (hematoporphyrin-melanin nanoconjugates) Hematoporphyrin 4 T1 4 T1 US for 1, 3, 5, and 7 min Zhang et al. (2021a)
Cur-Au NPs-PEG Cur-Au NPs-PEG C540 (B16/F10) C540 (B16/F10) 1.0 W/cm2; 1 min Kayani et al. (2021)
TiN (ultra-small titanium nitride) nanodots TiN 4T1 4T1 40 kHz, 3.0 W/cm2 Wang et al. (2021b)
CD@Ti3C2Tx HJs Ti3C2Tx 4T1, MG-63, hMSCs 4T1 50 kHz, 3.0 W/cm2 Geng et al. (2021)
H–Ti3C2-PEG NSs Ti3C2 NSs (Ti3C2 MXene nanosheets) 4T1 4T1 <1 W/cm1; 10 min Li et al. (2022)
SDT/CDT/chemotherapy mZMD (mesoporous zeolitic-imidazolateframework@MnO2/doxorubicin) mZM HeLa HeLa 1.0 MHz, 50% duty cycle 1.0 W/cm2; 1 min Guan et al. (2022)
SDT/PDT/chemotherapy RBNs (RB-loaded peptido-nanomicelles) Rose Bengal (RB) CNE-2Z CNE-2Z 1.5 W/cm2, 3 min Liu et al. (2019)
OC (oleanolic acid-Ce6) Ce6 PC9, 4T1 4T1 400 mW/cm2, 2 min Zheng et al. (2021a)
SDT/PDT/PTT PAIN (peptide amphiphile-ICG nanomicelles) PAIN MDA MB-231 MDA MB-231 1.5 W/cm2, 5 min Liu et al. (2020)
SDT/Gas therapy/Immunotherapy iCRET NPs iCRET NPs CT26, 4T1, and 4T1-Luc CT26 5 min (100 s × 3 points) Jeon et al. (2022)
SDT/Autophagy CCM-HMTNPs/HCQ HMTNPs MCF-7 MCF-7 1 W cm2; 30 s Feng et al. (2019)
ACHL (angiopep-2 peptide-modified-liposomes co-loaded with Ce6 and HCQ) Ce6 GL261 GL261 1.0 MHz, duty cycle: 20%, ultrasound power:1 W, burst interval time: 1 s, duration time: 60 s Qu et al. (2020)
PpIX/3-MA@Lip PpIX MCF-7 MCF-7 1.0 MHz, 1.5 W/cm2, 50% duty cycle Zhou et al. (2021)
2.3.1 Sonodynamic therapy with chemotherapy

As one of the commonly adopted clinical therapies against cancer, chemotherapy applies chemotherapeutic drugs with high toxicity to tumor cells. However, severe systemic side effects caused by chemotherapy have always been the major challenge for this tumor therapy. It is suggested that combining chemotherapy with SDT can lead to significantly improved synergistic therapeutic effects with reduced systemic toxicity (Shen et al., 2015; Shi et al., 2015; Nesbitt et al., 2018; Logan et al., 2019; Liang et al., 2020a; Xu et al., 2020b). Chemotherapy often leads to multidrug resistance, which can cause tumor recurrence and metastasis. Combining SDT with chemotherapy has shown great advantages in overcoming drug resistance owing to controlling the release of drugs and increasing cell membrane permeability (Wan et al., 2016a; Chen et al., 2017a; Liu et al., 2017; Li et al., 2018; Liang et al., 2020b; Guan et al., 2022). Moreover, SDT was found to promote cancer cells’ drug sensitivity by improving cellular internalization of chemotherapeutic drugs, activating the mitochondria-caspase signaling pathway, and down-regulating the expression of ATP-binding cassette transporters (Ding et al., 2017; Xu et al., 2020a; Ren et al., 2022). These functions enhanced the cytotoxicity of chemotherapeutic factors and therefore contributed to the promoted therapeutic efficiency (An et al., 2020a; Zhang et al., 2021b; Cao et al., 2021; Zhang et al., 2021c).

 2.3.2 Sonodynamic therapy with photodynamic therapy

SDT can also be combined with photodynamic therapy, named sono-photodynamic therapy (SPDT). SPDT could enhance intracellular ROS generation, severe mitochondria damage, cell migration inhibition, nuclear condensation, cell membrane permeability, and significantly trigger cell apoptosis (Wang et al., 2013a; Li et al., 2014a; Li et al., 2014b; Wang et al., 2015a; Liu et al., 2016; Atmaca et al., 2021). Nene and Nyokong (2021) designed a nanoplatform in which phthalocyanines (Pcs) were conjugated to nitrogen (NGQDs) and nitrogen-sulfur (NSGQDs) graphene quantum dots. The nanoparticles were irradiated with light for photodynamic therapy (PDT), ultrasound for sonodynamic therapy, and the combination of both in photo-sonodynamic therapy (PSDT). They found that only 1O2 was detected for PDT treatment. In contrast, both the 1O2 and •OH radicals were evident after SDT and PSDT treatments, and the combination therapy showed improved ROS generation efficacy compared to the monotherapies (Nene and Nyokong, 2021). Aksel et al. (2021) found that malondialdehyde (MDA) levels were increased while superoxide dismutase activity (SOD), catalase (CAT), and glutathione (GSH) levels were decreased after TiO2-mediated SPDT (Aksel et al., 2021).

 2.3.3 Sonodynamic therapy with gas therapy

Gas therapy has attracted much attention as a novel “green” cancer treatment strategy in recent years (Chen et al., 2019). To date, several gases, such as nitrogen (N2), and nitric oxide (NO), carbon oxide (CO), carbon dioxide (CO2), have been involved in these therapeutic approaches (Chen et al., 2019). When SDT is combined with gas therapy for tumor treatment, the US triggers gas donors to release and produce highly toxic products or change the disease condition to promote the tumor suppression effects (An et al., 2020b; Cheng et al., 2022; Zhu et al., 2022; Zuo et al., 2022). The generated gas bubbles could be used as a powerful US contrast agent that greatly enhances the US contrast to guide cancer therapy. Some nanoplatforms, such as Lip-AIPH, Au NR-mSiO2/AIPH, OCN-PEG-(Ce6-Gd3+)/BNN6, and HMME/MCC-HA, have been explored, which integrated coordinated functions of diagnostics and therapy (Feng et al., 2018; Lin et al., 2019; Zheng et al., 2021b; Ye et al., 2021).

 2.3.4 Sonodynamic therapy with immunotherapy

As a promising therapeutic modality for cancer treatment, immunotherapy, which stimulates the host tumor-specific innate and acquires systemic immune responses to attack cancer cells, is different from other traditional cancer therapies that directly target malignant cells (Li et al., 2021; Liang et al., 2021). Furthermore, immunotherapy can ablate localized tumors, inhibit distant tumors, and suppress tumor metastasis. After immunotherapy, the host can form long-term immune memory to prevent tumor recurrence (Li et al., 2021; Liang et al., 2021). SDT can motivate immune responses by eliciting ICD (immunogenic cell death) induced by the production of cytotoxic ROSs to suppress tumor growth and prevent tumor recurrence effectively (Li et al., 2020; Cheng et al., 2021; Yin et al., 2021). PFCE@THPPpf-COPs designed by Yang et al. (2022) can attenuate tumor hypoxia and suppress tumor growth by inducing ICD of cancer cells. After combining with anti-CD47 immunotherapy, this synergistic treatment exhibited potent protective memory antitumor immunity to prevent tumor recurrence (Yang et al., 2022). Some smart SDT platforms that induced potent antitumor immune responses were designed in recent years, such as MON-PpIX-LA-CO2 (Yin et al., 2021), DYSP-C34 (Wang et al., 2021a), TiO2@CaP (Tan et al., 2021), membrane-coated Fe-PDAP/Ce6 (Jiang et al., 2022), Zn-TCPP/CpG (Zhu et al., 2020b), and so on. Immunotherapy has great potential to be combined with SDT to achieve more effective cancer treatments. Yue et al. (2019) combined noninvasive SDT with checkpoint blockade immunotherapy by the nanosonosensitizers HMME/R837@Lip to induce an anti-tumour response, and this combination arrested primary tumor progression and prevented lung metastasis. Other nanocarriers combining SDT with immunotherapy were also developed, such as TIR@FITC-Nrf2-siRNA (Wan et al., 2021), TiO2-Ce6-CpG (Lin et al., 2021), PEG-CDM-aPD-L1/Ce6 (Huang et al., 2021) and this combinatorial tumor therapeutics can robust anti-cancer immunity and long-term immune memory (Table 3).

 2.3.5 Sonodynamic therapy with other therapies

Materials with high absorbance in the NIR-II region could be applied in photo-induced cancer therapy. The photothermal effect could prolong blood circulation and improve the O2 supply, promoting ROS generation (Wang et al., 2021b; Geng et al., 2021; Li et al., 2022). The thermal effect in photothermal therapy can boost the efficiency of SDT and achieve synergistically enhanced therapeutic purposes (Zhang et al., 2021a; Kayani et al., 2021). At the same time, researchers have found that SDT can induce protective autophagy, which significantly reduces the efficiency of SDT, making it possible to combine SDT with autophagy to enhance the therapeutic efficacy (Feng et al., 2019; Liang et al., 2020a; Qu et al., 2020; Zhou et al., 2021).

 3 Autophagy 3.1 Overview of autophagy pathway

Autophagy can be divided into three types according to the role of lysosomes, including macroautophagy, microautophagy, and chaperone-mediated autophagy. Macroautophagy (referred to autophagy) is a process in which cells can form double-membraned autophagic vesicles named autophagosome that sequesters damaged organelles and misfold proteins and fuse with lysosome to form autolysosome for degradation (Figure 2) (Antonioli et al., 2017; Zhao et al., 2021). Microautophagy refers to a process in which misfolded proteins or damaged organelles are directly wrapped by lysosomal traps without forming autophagosomes. Molecular chaperone mediated autophagy refers to the process in which substrate protein is bound to lamp-2A receptor on lysosome by molecular chaperone such as HSP70, mediating its degradation (Bandyopachyay and Cuervo, 2008). Therefore, the autophagy process discussed in this paper is macroautophagy, referred to as autophagy.

The autophagy pathway. There are 6 steps in the autophagy pathway. Step 1 Initiation: activation of ULK1 complex and multiple ATG proteins are engaged and localized to PAS. Under nutrient-rich conditions, mTORC1 phosphorylates ATG13 and ULK1/2 and blocks the interaction of ATG13 with ULK1/2, FIP200, and ATG101 to inactivate them (Hosokawa et al., 2009a; Hosokawa et al., 2009b; Park et al., 2016). When treated with rapamycin or under starvation conditions, mTORC1 dissociates from the complex and partially dephosphorylates these sites resulting in the complex anchors to a pre-autophagosomal structure (PAS) that recruits autophagy-related (ATG) proteins onto it to initial autophagy (Chan, 2009). Steps 2 Nucleation: ATG12 conjugation system and LC3 conjugation system are recruited to form phagophore. The ubiquitin-like protein ATG12 activated by the E1 enzyme ATG7 and E2 conjugating enzyme ATG 10 is irreversibly conjugated to ATG5 (Geng and Klionsky, 2008; Nakatogawa, 2013). The ATG12–ATG5 conjugate binds ATG16L1 with a lysine residue (K) in ATG5 to form the ATG16L1 complex (Hanada et al., 2007). The dimerization of ATG16L promotes membrane expansion (Ishibashi et al., 2011). ProLC3 is first cleaved by the cysteine protease ATG4 to expose their C termini glycine residue to form LC3-I (Satoo et al., 2009). LC3-I is activated by the E1 enzyme ATG7 and transferred to E2 enzyme ATG3, and the ATG16L complex exerts E3 enzyme activity that promotes the lipid conjugation of PE to LC3-I to form LC3-II for autophagosome formation (Kabeya et al., 2000; Fujita et al., 2008; Satoo et al., 2009; Nakatogawa, 2013). Step 3 Elongation: lipid enrichment supports a complex ubiquitin-like conjugation system that results in the conjugation of LC3 family members to the lipid phosphatidylethanolamine (PE) on phagophore. LC3 serves as a docking site for cargo adaptors that enable cargo loading into the AV. Step 4 Maturation: completion and transport of the autophagosome. ATG9-positive vesicles are delivered trans-Golgi apparatus, recycling endosome, and plasma membrane to contribute autophagosome maturation (Ravikumar et al., 2010; Takahashi et al., 2011; Orsi et al., 2012; Imai et al., 2016). Step 5 Fusion: autophagosome fuses lysosome to form autolysosome. Step 6 Degradation and recycling: degradation of cargo inside autolysosome and recycling of nutrients.

 3.1.1 Initiation

Induction of autophagosome formation is regulated by the Unc-51-like kinase (ULK) complex, which is made up of a ULK family kinase (ULK1 and ULK2), autophagy-related gene 13 (ATG13), RB1-inducible coiled-coil 1 (RB1CC1/FIP200) and ATG101 (Hara et al., 2008; Chan, 2009; Zachari and Ganley, 2017).

 3.1.2 Nucleation, elongation, and maturation

The phosphatidylinositol 3-phosphate kinase (PI3K) complex consists of VPS34, BECN 1, ATG14L, and p150. Next, NRBF2 is recruited to the putative site of autophagosome formation (Matsunaga et al., 2009; Lu et al., 2014). Phosphatidylinositol (PI) in isolation membrane or omegasome is phosphorylated by the PI3K complex to produce phosphatidylinositol 3-phosphate (PtdIns3P), which recruits multiple PtdIns3P-binding proteins to regulate autophagosome formation. ATG12 conjugation system and LC3 conjugation system are involved in elongation. The ATG12-conjugation system includes ATG12, ATG7, ATG10, ATG5, and ATG16L. The LC3-conjugation system includes ProLC3, ATG4, LC3-I, ATG7, ATG3, and LC3-II (LC3-I/PE). The ATG9A/ATG2-WIPI1/2 trafficking system consisting of ATG9A, ATG2, and WIPI1/2 is also involved in autophagosome precursor formation.

 3.1.3 Fusion

The fusion of autophagosomes with functional endolysosomal compartments (early endosomes, late endosomes, and lysosomes) is required for autophagosome maturation, which is regulated by RABs, tethers (HOPS), and the SNARE complex (Itakura et al., 2012; Jiang et al., 2014; Tsuboyama et al., 2016; Shen et al., 2021).

 3.1.4 Degradation and recirculation of autophagosomal contents

When autophagosome fuses with lysosomes to form autolysosome, autophagic cargo such as misfolded protein and damaged organelles are degraded by lysosomal hydrolases as well as the inner membrane of the autophagosome is degraded into amino acids or peptides for recycling by cells (Mony et al., 2016; Yim and Mizushima, 2020).

 3.2 Relationships between autophagy and tumor

Research has shown that the occurrence and development of tumors are closely related to autophagy. Autophagy is deemed an evolutionarily conserved catabolic process in mammalian cells (Glick et al., 2010; Amaravadi et al., 2019). In the autophagy process, a double-membrane autophagosome with a sequestrated intracellular component is delivered and fused with lysosomes for degradation (Parzych and Klionsky, 2014). Recycling these materials can provide energy for the survival of cells under a variety of stress conditions (Glick et al., 2010; White et al., 2015; Kocaturk et al., 2019). The protein aggregates and damaged organelles are also removed to ensure cell homeostasis and quality control (Glick et al., 2010; Kocaturk et al., 2019). Autophagy regulates various physiological functions such as stress resistance, cell death determination, and tissue remodeling. For human cancers, large-scale genomic analysis reveals that it is uncommon to lose or mutate core autophagy genes (Amaravadi et al., 2016). However, oncogenic events that activate autophagy and lysosome biogenesis are identified (Amaravadi et al., 2016). In addition, autophagy can promote cellular senescence and cell surface antigen presentation, which prevents genome instability and necrosis and finally prevents cancer (Glick et al., 2010). Autophagy impacts the interaction between the tumor and the host by assisting stress adaption and eliminating activation of adaptive immune responses. In addition, autophagy helps the crosstalk between the tumor and the stroma, which assists tumor growth under different stress conditions. Therefore, the factors influencing autophagy in cancer include microenvironment stress, starvation level, and the immune system (Amaravadi et al., 2016).

The dichotomous role of autophagy in tumor cells is elaborated in detail. On the one hand, in normal cells, the basal level of autophagy is crucial in ensuring protein quality control by removing misfolded proteins and preventing the accumulation of damaged DNA from maintaining genetic stability. As a result, the autophagy process can suppress the formation of tumor cells. At the early stage some tumors can undergo autophagic cell death (ACD) through the induction of autophagy by some anticancer drugs, in which progress autophagy plays a pro-death role (Amaravadi et al., 2016). On the other hand, autophagy can help tumor cells adapt to diverse adverse environments by providing nutrients and removing cytotoxic substances under stress, thus assisting tumor cell survival. In these circumstances, autophagy plays a pivotal cytoprotective role in promoting malignant tumors’ proliferation, invasion, and metastasis (White et al., 2015). In brief, autophagy acts as a double-edged sword (can have both pro-survival e and pro-death effects) in tumor occurrence, development, and metastasis (Helgason et al., 2013; Levy et al., 2017; Yun and Lee, 2018; Amaravadi et al., 2019).

 4 The crosstalk of sonodynamic therapy and autophagy 4.1 Sonodynamic therapy induced autophagy

SDT triggers autophagy (or macroautophagy), which can be divided into two conditions in cancer therapy and lipid metabolism, as summarized in Figure 3. SDT-induced autophagy represents a double-edged sword, and a combination SDT with autophagy inhibition/activation strategies is summarized in Table 4.

The mechanism of autophagy induction by SDT. ROS triggers mitochondria-apoptosis, which induces protective autophagy through the PINK/Parkin pathway in cancer therapy. SDT can inhibit chemotherapy sensitivity by ROS-induced ER stress, which activates autophagy in PI3K/AKT/mTOR pathway. Red arrow for cancer therapy, blue arrow for drug resistance in cancer therapy.

Summary the autophagy activation of SDT.

Type of cancer cell line Sonosensitizer Autophagy role References
Murine leukemia L1210 cells Protoporphyrin IX (PpIX) Pro-survival Wang et al. (2013b)
4T1 cells Ce6 Pro-survival Li et al. (2014a)
K562cells Protoporphyrin IX (PpIX) Pro-survival Su et al. (2015)
THP-1-derived macrophage Hypericin Pro-death Li et al. (2016b)
THP-1 macrophages Berberin Pro-death Kou et al. (2017)
THP-1 macrophages Hydroxysafflor yellow A Pro-death Jiang et al. (2017)
PTX-resistant PC-3 cells — Pro-survival Wu et al. (2018)
MCF-7 cells 5-ALA Pro-survival Song et al. (2018)
MCF-7 cells Hollow mesoporous titanium dioxide nanoparticles (HMTNPs) Pro-survival Feng et al. (2019)
GL261 cells Ce6 Pro-survival Qu et al. (2020)
4T1 cells HMME@HMONs-3BP-PEG Pro-death Zou et al. (2021)
MCF-7 cells Protoporphyrin IX (PpIX) Pro-survival Zhou et al. (2021)
B16-F0 mouse melanoma cells Ce6 Pro-death Zhang et al. (2022)
4.1.1 In cancer therapy

The ultimate target of all anti-tumor therapies is to kill the tumor cells effectively and specifically. Cell death is classified into three types: apoptosis, autophagy, and necrosis (Kitanaka and Kuchino, 1999). Up to now, the major method in anti-tumor therapy is to induce apoptosis. However, tumor cells can escape from apoptosis with multiple pathways triggered by the anti-tumor treatments, among which autophagy is a novel cellular response and is attracting increasing attention (Hsin et al., 2011). Autophagy protects tumor cells from various stimuli, including amino acid deficiency, hypoxia, DNA and mitochondrial damage, and oxidative stress (Amaravadi et al., 2016). With SDT, the tumor cells suffer from various environmental stresses, and therefore autophagy is promoted to assist the tumor cell survival. As a result, the efficiency of SDT is significantly reduced. Many researchers have carried out investigations on SDT-induced autophagy in different tumor cells.

Su et al. (2015) investigated the interplay between apoptosis and autophagy induced by SDT in leukemia K562 cells. Under the protoporphyrin IX (PpIX)-mediated SDT, with the techniques of morphological observation and biochemical analysis, the mitochondrial-dependent apoptosis was noted. At the same time, SDT was observed to promote Autophagy in K562 cells and caused an increase in EGFP-LC3 puncta cells, conversion of LC3 II/I, formation of autophagosome, and co-localization between LC3 and LAMP2 (a lysosome marker). It was proposed that the SDT-induced autophagy is a cytoprotective mechanism because the autophagy inhibitor 3-MA or bafilomycin A1 was shown to suppress autophagy and enhance the SDT-induced apoptosis and necrosis. Experimental data suggested that the ROS caused by PpIX-SDT treatment may play an important role in inducing autophagy. Wang et al. (2013b) investigated the potential inductions of autophagy. Many signaling pathways are involved in the SDT-induced autophagy, such as those related to the control of mitochondria damage and ROS generation. Mitochondria can be a source of ROS and a target of oxidative damage during oxidation stress. In the experiments, the generation of ROS after SDT diffuses the whole cells, including mitochondria, and the accumulated ROS significantly affects the normal functions of the mitochondria. The damaged mitochondria co-localized rapidly with the autophagosome marker, which suggested that mitochondria damage can be one of the triggers for the induction of autophagy. In addition, ROS was also found to be involved in SDT-induced autophagy. Song et al. (2018) proposed the PINK1/Parkin-dependent signaling pathway to initiate mitophagy and autophagy in the human breast adenocarcinoma cell line MCF-7 cells subjected to SDT. The 5-aminolevulinic acid was used as the sonosensitizer. Excessive productions of ROS caused by SDT, together with the PINK1/Parkin-dependent signaling pathway, acted together to initiate mitophagy. The initiated mitophagy and autophagy helped protect the tumor cells against SDT-induced cell death. Qu et al. (2020) designed an “all-in-one” nanosensitizer platform that incorporated Ce6 and HCQ into angiopep-2 peptide-modified liposomes named ACHL. They found that SDT triggered mitophagy dependent on MAPK/p38 activation, which attenuated apoptosis in glioblastoma cells.

It is worth noting that SDT can enhance chemotherapy sensitivity and reverse drug resistance in tumor cells. At the same time, important clues has been emerged that autophagy promotes tumor drug resistance by involves the changes of apoptotic signals (Chang and Zou, 2020). The inhibition of Hedgehog (Hh) signaling pathway induces autophagy in BCR-ABL+ CML cells. Simultaneously inhibiting the Hh pathway and autophagy overcome CML drug resistance (Zeng et al., 2015). Many studies have shown that the addition of inhibitors of the PI3K/AKT/mTOR pathway can effectively enhance tumor therapy (Chang et al., 2013; Rangwala et al., 2014; Zeng et al., 2015). Wu et al. (2018) found that autophagy was induced in paclitaxel-resistant PC-3 cells after SDT treatment. A possible mechanism for promoting autophagy in paclitaxel-resistant PC-3 cells after SDT was the endoplasmic reticulum stress-mediated PI3K/AKT/mTOR signaling pathway. In the experiments, the observation of autophagy was realized by TEM and fluorescence microscopy. After SDT, the inhibition of PI3K/AKT/mTOR signaling pathway by endoplasmic reticulum stress-induced autophagy and autophagy reduced endoplasmic reticulum stress by eliminating the elimination of misfolded proteins and reactive oxygen species. It was further found that autophagy inhibition promoted endoplasmic reticulum stress, therefore down-regulating the PI3K/AKT/mTOR signaling pathway and finally leading to cell death (Wu et al., 2018).

 4.2 Combining autophagy inhibition with sonodynamic therapy in cancer therapy

Considering the unfavorable effects of autophagy induced by SDT, many researchers suggested that the combination of SDT with autophagy inhibition can improve the efficiency of tumor therapy (Wang et al., 2010a). The role of autophagy in SDT-induced cytotoxicity in S180 cells was investigated by Wang et al., and an autophagy inhibitor study was performed. Through ample experiments, the autophagy inhibitors significantly promoted the SDT-induced cell death. Specifically, autophagy can participate in SDT-induced cell death, and the inhibition of autophagy at an early stage can promote the tumor treatment efficiency of SDT by the inducted apoptosis and necrosis. Autophagy was detected in the S180 cells treated with SDT under TEM. Double membrane-enclosed vacuoles containing damaged cellular components were observed with TEM. The autophagosomes and autolysosomes involved in this process were further confirmed by the immunofluorescence method. Western blot analysis showed that after SDT, autophagy flux happened in the early stage of cell damage. Kessel and Oleinick raised a similar point that within 1 hour following PDT, the PDT-induced autophagy can be detected. The results showed that with the application of autophagy inhibitors 3-methyladenine or Bafilomycin A1, after 1 hour following SDT, the loss of mitochondria membrane potential greatly increased, and therefore inhibiting autophagy can accelerate SDT induced cell death (Kessel and Oleinick, 2009).

Su et al. (2015) reported that intensified autophagy in human chronic myelogenous leukemia K562 cells was induced by protoporphyrin IX (PpIX) mediated SDT, and the induced autophagy was related to the up-regulation of Beclin-1 and the autophagic vacuoles observed in the SDT treated K562 cells. In the experiments, transfection of Beclin-1 shRNA inhibited the conversion of LC3 II/I and autophagic vacuoles significantly, which showed that autophagy was inhibited due to shRNA caused down-regulating of Beclin-1. In addition, compared with SDT only, the combined treatment with Beclin-1 shRNA led to more severe cytotoxicity. It was, therefore, demonstrated that SDT promoted autophagy of K562 cells significantly, autophagy might exert a self-protective effect against sonodamage for K562 cells, and finally, autophagy inhibition promoted cell apoptosis induced by SDT effectively.

The promising role of autophagy for drug development in cancer treatment was discussed. The state-of-art autophagy targeting methods and the potential role of autophagy in tumor immunity were thoroughly studied and reported. Autophagy suppressed tumor initiation but promoted advanced tumor growth. It was further found that autophagy inhibition could be sensitive and effective in advanced cancer therapy (Tanida, 2011). A variety of autophagy inhibitors in clinical trials and laboratory research were discussed, among which hydroxychloroquine (HCQ) treatment was found to be effective in cancer treatment (Shi et al., 2017). The combination of HCQ with other chemicals as the autophagy inhibitor for cancer therapy was also discussed (Goldberg et al., 2012; Cook et al., 2014; Mahalingam et al., 2014; Rangwala et al., 2014; Rosenfeld et al., 2014; Vogl et al., 2014). To conclude, the autophagy inhibitor plays a promising role in tumor treatment. Autophagy inhibitors were summarized in Table 5. Still, research on a suitable autophagy inhibitor with superior targeting, high efficiency, good sensitivity, and low toxicity is further needed. The initiation of autophagy by protoporphyrin IX (PpIX) mediated SDT in murine leukemia L1210 cells was examined by Wang et al. (2013b) Experiments showed that autophagy was protective for tumor cells after SDT and therefore impairment of autophagy can enhance the anti-tumor effect. Experimental data suggested that autophagy inhibition accelerated apoptosis and necrosis of SDT-treated tumor cells. A treatment combining autophagy inhibitors with SDT promotes tumor cell death and will be a promising method for cancer therapy.

Summary of autophagy inhibitors.

Drugs Target Biological models Status of the study Biological effects References
Chloroquine (CQ) Lysosomal pH Human breast cancer MCF-7 cells; human colorectal cancer cells Approved by FDA; phase I clinical trial Inhibition of protective autophagy by blocking autophagosome fusion and degradation; autophagy inhibition at the late stage of the pathway; evidence of preliminary antitumor activity Sui et al. (2013)
Hydroxychloroquine (HCQ) Lysosomal pH Human esophageal, hepatocellular carcinoma, lung, and pancreatic cancer cells Approved by FDA; phase I clinical trial Inhibition of autophagosome fusion with lysosomes and autophagosome degradation; autophagy inhibition at the late stage of the pathway; induction of autophagic tumor cell death; safely dose escalated in cancer patients Sui et al. (2013)
HCQ + tamoxifen Lysosomes, estrogen receptor-ɑ (ERɑ) Human breast cancer cells in female athymic mice In vivo models; cancer cell lines; phase I clinical trial Reduced drug resistance; In vitro and in vivo promotion of antiestrogenic therapy Cook et al. (2014)
HCQ + temsirolimus Lysosomes, mTOR pathway Human renal carcinoma cell lines Cancer cell lines Induction of apoptosis and cell death; promotion of mitochondrial damage with mTOR down-regulation; tumor growth suppression Lee et al. (2015)
3- methyladenine (3-MA) Autophagosome formation, class III PI3K inhibitor Human chronic myelogenous leukemia K562 cell line Cancer cell lines Inhibition on the formation of autophagosomes; autophagy inhibition at the early stage of the pathway; aggravated chromatin condensation; enhanced SDT-induced apoptosis and necrosis Su et al. (2015)
Bafilomycin A1 (Ba A1) Autophagolysosome formation, vacuolar-type H (+)-ATPase inhibitor Murine sarcoma S180 cell line Cancer cell lines Inhibition on the fusion between autophagosomes and lysosomes; autophagy inhibition at the late stage of the pathway; enhanced SDT induced caspase-3 and PARP cleavage; enhanced SDT-induced cell death and anti-tumor effect Wang et al. (2010a)
Monensin Endocytic and lysosomal pH Human non-small lung cancer NCI-H1299 cell line Cancer cell lines Inhibition on the fusion between autophagosomes and lysosomes; autophagy inhibition at the late stage of the pathway; enhanced cell cycle arrest and apoptosis; tumor growth suppression Choi et al. (2013)
Wortmannin Autophagosome formation, class III PI3K inhibitor Hepatocytes from male wistar rats Cells Inhibition of autophagosome formation; potent inhibition of mammalian PtdIns 3-kinase; autophagy inhibition at the early stage of the pathway Wang et al. (2010b)
2- (4-morpholinyl)-8-phenyl-chromone (LY294002) Autophagosome formation, class III PI3K inhibitor Chinese hamster ovary (CHO) cell line CHO cell lines Inhibition of autophagosome formation; promotion of rolipram-induced PDE4A4 aggregate/foci formation; potent inhibition of autophagic sequestration; autophagy inhibition at the early stage of the pathway Christian et al. (2010)

Based on the above literature review, it is clearly identified that both SDT and autophagy inhibition has great potential in tumor therapy. To encounter the limitations of traditional sonosensitizers, the nanoparticles-based sonosensitizers, which make use of nanoparticles to deliver the sonosensitizers to target tissues or tumor cells, were introduced and investigated. The combination of SDT with nanoparticles-based sonosensitizers and autophagy inhibition proves to be a superior therapy with high specificity and accuracy and improves the outcomes of traditional tumor treatment methods. As an innovative tumor treatment concept, few researchers have carried out investigations in this field. However, as Qu et al. (2020) and Feng et al. (2019) suggested, this combinational tumor therapy method is sensitive, effective, and safe.

Qu et al. (2020) designed a novel “all-in-one” nanosensitizer and improved the SDT efficiency in glioma therapy. The “all-in-one” nanosensitizer incorporates the sonoactive chlorin e6 (Ce6) and hydroxychloroquine (HCQ) into angiopep-2 peptide-modified liposomes (APL), in which APL acts as the NP platform for drug delivery, Ce6 acts as the sonosensitizer, and HCQ acts as the autophagy inhibitor. APL can selectively accumulate in the glioma cells in the brain, which is a good strategy for precise drug delivery and can help minimize the side effects of the applied drugs on orthotopic cells. As the autophagy helps tumor cells adapt to oxidative injury and other stress after SDT by recycling the damaged mitochondria, the autophagy inhibitor HCQ prevents the above process and significantly enhances the SDT therapeutic effect. The mechanism of autophagy inhibitor improving SDT efficiency was proposed in this review as the autophagy blockage can enhance oxidative damage and increase the apoptosis response (Figure 4).

Schematic of “all-in-one” nanosensitizer platform. An “all-in-one” nanosensitizer platform by incorporating Ce6 and HCQ into angiopep-2 peptide-modified liposomes (designated ACHL) for orthotopic glioma theranostics was designed. An initial ultrasonic pulse (US1) destroyed the microbubbles and promoted the ACHL into the reversibly opened BBB, while a second ultrasonic stimulus (US2) generated the SDT effects. SDT-mediated mitophagy and its inhibition by HCQ were evaluated, along with the anti-glioma effects. The MAPK/p38 signaling pathway contributed to the progression of mitophagy induced by nanoCe6-SDT.

A similar therapeutic method was reported by Feng et al. (2019), in which the sonosensitizer hollow mesoporous titanium dioxide NPs (HMTNPs), along with the autophagy inhibitor HCQ, were combined and coated with cancer cell membranes (CCM). The biomimetic CCM coating allowed the CCM-HMTNPs/HCQ drugs to be delivered to target tumor cells. Under US irradiation during SDT, HCQ was released to block the autophagy process. Moreover, the vessel normalization effect of HCQ improved the tumor cell hypoxia situation, which significantly promoted the oxygen-dependent HMTNPs-mediated SDT (Figure 5). It was concluded that the CCM-HMTNPs/HCQ drugs highly enhanced the sensitivity and efficiency of SDT on breast tumor cells (Feng et al., 2019).

Schematic of the Cancer Cell Membrane Biomimetic Nanoplatform. (A) formulation of CCM-HMTNPs/HCQ, (B) vessel normalization effect of HCQ for enhancing the oxygen-dependent SDT treatment, and (C) schematic mechanism of CCM-HMTNPs/HCQ for enhanced SDT on breast cancer via autophagy regulation strategy. Copyright 2019, ACS Applied Materials & Interfaces.

Zhou et al. (2021) constructed an “all-in-one” nanoliposomes co-encapsulating sonosensitizers protoporphyrin IX (PpIX) and autophagy inhibitor 3-MA. It has been demonstrated that SDT induced cytoprotective pro-survival autophagy with alleviating apoptosis through the MAPK signaling pathway. Combining SDT and autophagy blockage significantly decreased the cell resistance to intracellular oxidative stress and resulted in a remarkable synergistic effect on cancer therapy (Figure 6).

Engineering PpIX/3-MA@Lip nanosonosentizer for synergistic SDT nanotherapeutics and autophagy blockage on combating cancer. The synthetic procedure of PpIX/3-MA@Lip nanosonosensitizers and schematic illustration of “all-in-one” strategy for cellular mechanism on SDT-induced cytoprotective autophagy and autophagy inhibition-enhanced antitumor efficacy of SDT. Enhanced production of intracellular ROS radicals by PpIX sonosensitizers-based SDT induced cytoprotective pro-survival autophagy. The integrated 3-MA inhibited the formation of autophagosomes in early-phase autophagy to eliminate the recycling nutrients for fulfilling the needs of cancer-cell adaptation and growth, which significantly induced the cancer-cell apoptosis and death. Copyright 2021, Journal of Nanobiotechnology.

Therefore, applying autophagy inhibitors to improve the sensitivity of SDT in tumor therapy is expected to provide a new and promising strategy to increase the SDT efficiency and sensitivity.

 5 Summary and outlook

Originated and developed from PDT, SDT is a novel non-invasive tumor therapy. The advantages of SDT include deep tissue penetration, high precision, low side effects, and good patient compliance. SDT refers to the “cavity effect” generated by the irradiation of ultrasound at a specific frequency on tumors in deep tissues. Under US irradiation, the sonosensitive accumulated by tumor cells changes them from the ground state to the excited state and reacts with surrounding oxygen molecules to produce a large number of ROS, resulting in tumor cell death. SDT has made great progress in the treatment of tumors, and there have been many studies on the treatment of pancreatic cancer, liver cancer, breast cancer and other deep tumors. How to improve the efficiency of SDT is still the focus and difficulty of sonodynamic research.

Firstly, the efficiency of SDT highly relies on the sonosensitizer, and the major challenge for the application of SDT lies in the poor sonosensitizer delivery accuracy. With the development of nanotechnology, NPs are introduced to deliver the sonosensitizers to target tissues or tumor cells with high specificity. Many researchers have investigated the suitable NPs to be used as target delivery carriers, which are reviewed in this paper. Secondly, the main mechanism of SDT is that US uses oxygen in tumor cells to produce a large number of ROS to destroy tumor cells. Increasing the production of ROS can fundamentally improve the efficacy of SDT. Studies have shown that reactive oxygen species can activate autophagy through a variety of pathways, degrade damaged proteins and organelles in cells, and mediate cell survival or death. Wang et al. (Wang et al., 2013a; Wang et al., 2013b) found that SDT activated autophagy while inducing apoptosis, and the activated autophagy inhibited apoptosis and protected tumor cells in 2013. Many successive studies have found that SDT-activated autophagy depends on ROS production, and activated autophagy helps tumor cells survive, which was summarized in this paper. It is speculated that avoiding the activation of protective autophagy during SDT can effectively improve the treatment sensitivity. State of the art therapeutic technique is the combination of SDT with nanoparticles-based sonosensitizers together with autophagy inhibition, which proves to be a superior therapy with high specificity and accuracy and improves the outcomes of traditional tumor treatment methods. Few investigations have been done in this area and are summarized in this review. Qu et al. (2020) used Angiopep-2 peptide modified liposomes to deliver Ce6, an acoustic sensitizer, and HCQ, an autophagy inhibitor, simultaneously to improve the acoustic dynamic therapy effect of glioma. Feng et al. (2019) used hollow mesoporous titanium dioxide nanoparticles to deliver the autophagy inhibitor HCQ and improve the SDT effect of breast cancer. Zhou et al. (2021) used liposomes to deliver acoustic sensitizer PpIX/autophagy inhibitor 3-MA synchronously, improving the therapeutic effect of acoustic dynamics on breast cancer.

Increasing the accumulation of sonosensitive agents in tumor sites using nanocarriers can increase the production of ROS, and then fundamentally improve the efficiency of sonodynamic therapy. The increase of ROS activated protective autophagy to inhibit the SDT efficacy. Therefore, it is speculated that the combination of targeted delivery of sonosensitizer and inhibition of autophagy can not only effectively kill tumor cells by increasing the production of ROS, but also avoid the activation of protective-autophagy by ROS. The findings in this review suggest that this is a promising tumor therapy, and more investigations need to be carried out in this area.

 Author contributions

YjZ wrote the draft manuscript. YrZ, YyZ, and QL provided revised suggestions for this manuscript. MZ and KT supervised the manuscript and provided financial support.

 Funding

This work was supported by the National Natural Science Foundation of China (No. 82000523), the Natural Science Foundation of Shaanxi Province of China (No. 2020JQ-095), and the “Young Talent Support Plan” of Xi’an Jiaotong University, China (No. YX6J001).

We would like to thank Shiwen Zhang for manuscript summarizing and editing work.

 Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

 Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

 References Aksel M. Kesmez O. Yavas A. Bilgin M. D. (2021). Titaniumdioxide mediated sonophotodynamic therapy against prostate cancer. J. Photochem. Photobiol. B 225, 112333. 10.1016/j.jphotobiol.2021.112333 Amaravadi R. Kimmelman A. C. White E. (2016). Recent insights into the function of autophagy in cancer. Genes Dev. 30 (17), 1913–1930. 10.1101/gad.287524.116 Amaravadi R. K. Kimmelman A. C. Debnath J. (2019). Targeting autophagy in cancer: Recent advances and future directions. Cancer Discov. 9 (9), 1167–1181. 10.1158/2159-8290.cd-19-0292 An J. Hu Y. G. Cheng K. Li C. Hou X. L. Wang G. L. (2020a). ROS-augmented and tumor-microenvironment responsive biodegradable nanoplatform for enhancing chemo-sonodynamic therapy. Biomaterials 234, 119761. 10.1016/j.biomaterials.2020.119761 An J. Hu Y. G. Li C. Hou X. L. Cheng K. Zhang B. (2020b). A pH/Ultrasound dual-response biomimetic nanoplatform for nitric oxide gas-sonodynamic combined therapy and repeated ultrasound for relieving hypoxia. Biomaterials 230. 10.1016/j.biomaterials.2019.119636 Antonioli M. Di Rienzo M. Piacentini M. Fimia G. M. (2017). Emerging mechanisms in initiating and terminating autophagy. Trends biochem. Sci. 42 (1), 28–41. 10.1016/j.tibs.2016.09.008 Atmaca G. Y. Aksel M. Keskin B. Bilgin M. D. Erdoğmuş A. (2021). The photo-physicochemical properties and in vitro sonophotodynamic therapy activity of Di-axially substituted silicon phthalocyanines on PC3 prostate cancer cell line. Dyes Pigments 184, 108760. 10.1016/j.dyepig.2020.108760 Bandyopachyay U. Cuervo A. M. (2008). Entering the lysosome through a transient gate by chaperone-mediated autophagy. Autophagy 4 (8), 1101–1103. 10.4161/auto.7150 Buytaert E. Callewaert G. Hendrickx N. Scorrano L. Hartmann D. Missiaen L. (2006). Role of endoplasmic reticulum depletion and multidomain proapoptotic BAX and BAK proteins in shaping cell death after hypericin-mediated photodynamic therapy. FASEB J. 20 (6), 756–758. 10.1096/fj.05-4305fje Buytaert E. Matroule J. Y. Durinck S. Close P. Kocanova S. Vandenheede J. R. (2008). Molecular effectors and modulators of hypericin-mediated cell death in bladder cancer cells. Oncogene 27 (13), 1916–1929. 10.1038/sj.onc.1210825 Canaparo R. Varchi G. Ballestri M. Foglietta F. Sotgiu G. Guerrini A. (2013). Polymeric nanoparticles enhance the sonodynamic activity of meso-tetrakis (4-sulfonatophenyl) porphyrin in an in vitro neuroblastoma model. Int. J. Nanomedicine 8, 4247–4263. 10.2147/ijn.s51070 Cao J. Pan Q. Bei S. Zheng M. Sun Z. Qi X. (2021). Concise nanoplatform of phycocyanin nanoparticle loaded with docetaxel for synergetic chemo-sonodynamic antitumor therapy. ACS Appl. Bio Mat. 4 (9), 7176–7185. 10.1021/acsabm.1c00745 Cao W. J. Matkar P. N. Chen H. H. Mofid A. Leong-Poi H. (2016). Microbubbles and ultrasound: Therapeutic applications in diabetic nephropathy. Adv. Exp. Med. Biol. 880, 309–330. 10.1007/978-3-319-22536-4_17 Cavalli R. Marano F. Argenziano M. Varese A. Frairia R. Catalano M. G. (2018). Combining drug-loaded nanobubbles and extracorporeal shock waves for difficult-to-treat cancers. Curr. Drug Deliv. 15 (6), 752–754. 10.2174/1567201814666171018120430 Chan E. Y. (2009). mTORC1 phosphorylates the ULK1-mAtg13-FIP200 autophagy regulatory complex. Sci. Signal. 2 (84), pe51. 10.1126/scisignal.284pe51 Chang H. Zou Z. (2020). Targeting autophagy to overcome drug resistance: Further developments. J. Hematol. Oncol. 13 (1), 159. 10.1186/s13045-020-01000-2 Chang Z. Shi G. Jin J. Guo H. Guo X. Luo F. (2013). Dual PI3K/mTOR inhibitor NVP-BEZ235-induced apoptosis of hepatocellular carcinoma cell lines is enhanced by inhibitors of autophagy. Int. J. Mol. Med. 31 (6), 1449–1456. 10.3892/ijmm.2013.1351 Chen H. Zhou X. Gao Y. Zheng B. Tang F. Huang J. (2014). Recent progress in development of new sonosensitizers for sonodynamic cancer therapy. Drug Discov. Today 19 (4), 502–509. 10.1016/j.drudis.2014.01.010 Chen L. Cong D. Li Y. Wang D. Li Q. Hu S. (2017a). Combination of sonodynamic with temozolomide inhibits C6 glioma migration and promotes mitochondrial pathway apoptosis via suppressing NHE-1 expression. Ultrason. Sonochem. 39, 654–661. 10.1016/j.ultsonch.2017.05.013 Chen L. C. Zhou S. F. Su L. C. Song J. B. (2019). Gas-mediated cancer bioimaging and therapy. Acs Nano 13 (10), 10887–10917. 10.1021/acsnano.9b04954 Chen M. J. Xu A. R. He W. Y. Ma W. C. Shen S. (2017b). Ultrasound triggered drug delivery for mitochondria targeted sonodynamic therapy. J. Drug Deliv. Sci. Technol. 39, 501–507. 10.1016/j.jddst.2017.05.009 Cheng D. Wang X. Zhou X. Li J. (2021). Nanosonosensitizers with ultrasound-induced reactive oxygen species generation for cancer sonodynamic immunotherapy. Front. Bioeng. Biotechnol. 9, 761218. 10.3389/fbioe.2021.761218 Cheng L. Qiu S. Wang J. Chen W. Wang J. Du W. (2022). A multifunctional nanocomposite based on Pt-modified black phosphorus nanosheets loading with l-arginine for synergistic gas-sonodynamic cancer therapy. Colloids Surfaces A Physicochem. Eng. Aspects 638, 128284. 10.1016/j.colsurfa.2022.128284 Choi H. S. Jeong E.-H. Lee T.-G. Kim S. Y. Kim H.-R. Kim C. H. (2013). Autophagy inhibition with monensin enhances cell cycle arrest and apoptosis induced by mTOR or epidermal growth factor receptor inhibitors in lung cancer cells. Tuberc. Respir. Dis. 75 (1), 9–17. 10.4046/trd.2013.75.1.9 Christian F. Anthony D. F. Vadrevu S. Riddell T. Day J. P. McLeod R. (2010). p62 (SQSTM1) and cyclic AMP phosphodiesterase-4A4 (PDE4A4) locate to a novel, reversible protein aggregate with links to autophagy and proteasome degradation pathways. Cell. Signal. 22 (10), 1576–1596. 10.1016/j.cellsig.2010.06.003 Cook K. L. Wärri A. Soto-Pantoja D. R. Clarke P. A. Cruz M. I. Zwart A. (2014). Hydroxychloroquine inhibits autophagy to potentiate antiestrogen responsiveness in ER+ breast cancer. Clin. Cancer Res. 20 (12), 3222–3232. 10.1158/1078-0432.ccr-13-3227 Danno D. Kanno M. Fujimoto S. Feril L. B. Kondo T. Nakamura S. (2008). Effects of ultrasound on apoptosis induced by anti-CD20 antibody in CD20-positive B lymphoma cells. Ultrason. Sonochem. 15 (4), 463–471. 10.1016/j.ultsonch.2007.08.004 Didenko Y. T. McNamara W. B. Iii Suslick K. S. (2000). Molecular emission from single-bubble sonoluminescence. Nature 407 (6806), 877–879. 10.1038/35038020 Ding Y. Song Z. Liu Q. Wei S. Zhou L. Zhou J. (2017). An enhanced chemotherapeutic effect facilitated by sonication of MSN. Dalton Trans. 46 (35), 11875–11883. 10.1039/c7dt02600e Escoffre J. M. Deckers R. Bos C. Moonen C. (2016). Bubble-assisted ultrasound: Application in immunotherapy and vaccination. Adv. Exp. Med. Biol. 880, 243–261. 10.1007/978-3-319-22536-4_14 Feng Q. Yang X. Hao Y. Wang N. Feng X. Hou L. (2019). Cancer cell membrane-biomimetic nanoplatform for enhanced sonodynamic therapy on breast cancer via autophagy regulation strategy. ACS Appl. Mat. Interfaces 11 (36), 32729–32738. 10.1021/acsami.9b10948 Feng Q. Zhang W. Yang X. Li Y. Hao Y. Zhang H. (2018). pH/ultrasound dual-responsive gas generator for ultrasound imaging-guided therapeutic inertial cavitation and sonodynamic therapy. Adv. Healthc. Mat. 7 (5), 1700957. 10.1002/adhm.201700957 Forbes M. M. Steinberg R. L. O'Brien W. D. (2011). Frequency-dependent evaluation of the role of definity in producing sonoporation of Chinese hamster ovary cells. J. Ultrasound Med. 30 (1), 61–69. 10.7863/jum.2011.30.1.61 Fujita N. Itoh T. Omori H. Fukuda M. Noda T. Yoshimori T. (2008). The Atg16L complex specifies the site of LC3 lipidation for membrane biogenesis in autophagy. Mol. Biol. Cell 19 (5), 2092–2100. 10.1091/mbc.e07-12-1257 Gao H. J. Zhang W. M. Wang X. H. Zheng R. N. (2010). Adriamycin enhances the sonodynamic effect of chlorin e6 against the proliferation of human breast cancer MDA-MB-231 cells in vitro . Nan Fang. Yi Ke Da Xue Xue Bao 30 (10), 2291–2294. Geng B. Xu S. Shen L. Fang F. Shi W. Pan D. (2021). Multifunctional carbon dot/MXene heterojunctions for alleviation of tumor hypoxia and enhanced sonodynamic therapy. Carbon 179, 493–504. 10.1016/j.carbon.2021.04.070 Geng J. Klionsky D. J. (2008). The Atg8 and Atg12 ubiquitin-like conjugation systems in macroautophagy. 'Protein modifications: Beyond the usual suspects' review series. EMBO Rep. 9 (9), 859–864. 10.1038/embor.2008.163 Glick D. Barth S. Macleod K. F. (2010). Autophagy: Cellular and molecular mechanisms. J. Pathol. 221 (1), 3–12. 10.1002/path.2697 Goldberg S. B. Supko J. G. Neal J. W. Muzikansky A. Digumarthy S. Fidias P. (2012). A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer. J. Thorac. Oncol. 7 (10), 1602–1608. 10.1097/JTO.0b013e318262de4a Guan S. Liu X. Li C. Wang X. Cao D. Wang J. (2022). Intracellular mutual amplification of oxidative stress and inhibition multidrug resistance for enhanced sonodynamic/chemodynamic/chemo therapy. Small 18, e2107160. 10.1002/smll.202107160 Hachimine K. Shibaguchi H. Kuroki M. Yamada H. Kinugasa T. Nakae Y. (2007). Sonodynamic therapy of cancer using a novel porphyrin derivative, DCPH-P-Na(I), which is devoid of photosensitivity. Cancer Sci. 98 (6), 916–920. 10.1111/j.1349-7006.2007.00468.x Hanada T. Noda N. N. Satomi Y. Ichimura Y. Fujioka Y. Takao T. (2007). The Atg12-Atg5 conjugate has a novel E3-like activity for protein lipidation in autophagy. J. Biol. Chem. 282 (52), 37298–37302. 10.1074/jbc.C700195200 Hara T. Takamura A. Kishi C. Iemura S. Natsume T. Guan J. L. (2008). FIP200, a ULK-interacting protein, is required for autophagosome formation in mammalian cells. J. Cell Biol. 181 (3), 497–510. 10.1083/jcb.200712064 Harada Y. Ogawa K. Irie Y. Endo H. Feril L. B. Jr. Uemura T. (2011). Ultrasound activation of TiO2 in melanoma tumors. J. Control. Release 149 (2), 190–195. 10.1016/j.jconrel.2010.10.012 Helgason G. V. Holyoake T. L. Ryan K. M. (2013). Role of autophagy in cancer prevention, development and therapy. Essays Biochem. 55, 133–151. 10.1042/bse0550133 Hiraoka W. Honda H. Feril L. B. Kudo N. Kondo T. (2006). Comparison between sonodynamic effect and photodynamic effect with photosensitizers on free radical formation and cell killing. Ultrason. Sonochem. 13 (6), 535–542. 10.1016/j.ultsonch.2005.10.001 Hosokawa N. Hara T. Kaizuka T. Kishi C. Takamura A. Miura Y. (2009a). Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy. Mol. Biol. Cell 20 (7), 1981–1991. 10.1091/mbc.e08-12-1248 Hosokawa N. Sasaki T. Iemura S. Natsume T. Hara T. Mizushima N. (2009b). Atg101, a novel mammalian autophagy protein interacting with Atg13. Autophagy 5 (7), 973–979. 10.4161/auto.5.7.9296 Hou R. Liang X. Li X. Zhang X. Ma X. Wang F. (2020). In situ conversion of rose bengal microbubbles into nanoparticles for ultrasound imaging guided sonodynamic therapy with enhanced antitumor efficacy. Biomater. Sci. 8 (9), 2526–2536. 10.1039/c9bm02046b Hsin I. L. Ou C. C. Wu T. C. Jan M. S. Wu M. F. Chiu L. Y. (2011). GMI, an immunomodulatory protein from Ganoderma microsporum, induces autophagy in non-small cell lung cancer cells. Autophagy 7 (8), 873–882. 10.4161/auto.7.8.15698 Huang J. Liu F. Han X. Zhang L. Hu Z. Jiang Q. (2018). Nanosonosensitizers for highly efficient sonodynamic cancer theranostics. Theranostics 8 (22), 6178–6194. 10.7150/thno.29569 Huang J. Xiao Z. An Y. Han S. Wu W. Wang Y. (2021). Nanodrug with dual-sensitivity to tumor microenvironment for immuno-sonodynamic anti-cancer therapy. Biomaterials 269, 120636. 10.1016/j.biomaterials.2020.120636 Huang Z. (2005). A review of progress in clinical photodynamic therapy. Technol. Cancer Res. Treat. 4 (3), 283–293. 10.1177/153303460500400308 Imai K. Hao F. Fujita N. Tsuji Y. Oe Y. Araki Y. (2016). Atg9A trafficking through the recycling endosomes is required for autophagosome formation. J. Cell Sci. 129 (20), 3781–3791. 10.1242/jcs.196196 Ishibashi K. Fujita N. Kanno E. Omori H. Yoshimori T. Itoh T. (2011). Atg16L2, a novel isoform of mammalian Atg16L that is not essential for canonical autophagy despite forming an Atg12–5-16L2 complex. Autophagy 7 (12), 1500–1513. 10.4161/auto.7.12.18025 Itakura E. Kishi-Itakura C. Mizushima N. (2012). The hairpin-type tail-anchored SNARE syntaxin 17 targets to autophagosomes for fusion with endosomes/lysosomes. Cell 151 (6), 1256–1269. 10.1016/j.cell.2012.11.001 Jeon J. Yoon B. Song S. H. Um W. Song Y. Lee J. (2022). Chemiluminescence resonance energy transfer-based immunostimulatory nanoparticles for sonoimmunotherapy. Biomaterials 283, 121466. 10.1016/j.biomaterials.2022.121466 Jiang P. Nishimura T. Sakamaki Y. Itakura E. Hatta T. Natsume T. (2014). The HOPS complex mediates autophagosome-lysosome fusion through interaction with syntaxin 17. Mol. Biol. Cell 25 (8), 1327–1337. 10.1091/mbc.E13-08-0447 Jiang Q. Qiao B. Lin X. Cao J. Zhang N. Guo H. (2022). A hydrogen peroxide economizer for on-demand oxygen production-assisted robust sonodynamic immunotherapy. Theranostics 12 (1), 59–75. 10.7150/thno.64862 Jiang Y. Kou J. Han X. Li X. Zhong Z. Liu Z. (2017). ROS-dependent activation of autophagy through the PI3K/Akt/mTOR pathway is induced by hydroxysafflor yellow A-sonodynamic therapy in THP-1 macrophages. Oxid. Med. Cell. Longev. 2017, 8519169. 10.1155/2017/8519169 Kabeya Y. Mizushima N. Ueno T. Yamamoto A. Kirisako T. Noda T. (2000). LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. Embo J. 19 (21), 5720–5728. 10.1093/emboj/19.21.5720 Kaleta-Richter M. Kawczyk-Krupka A. Aebisher D. Bartusik-Aebisher D. Czuba Z. Cieślar G. (2019). The capability and potential of new forms of personalized colon cancer treatment: Immunotherapy and Photodynamic Therapy. Photodiagnosis Photodyn. Ther. 25, 253–258. 10.1016/j.pdpdt.2019.01.004 Kayani Z. Dehdari Vais R. Soratijahromi E. Mohammadi S. Sattarahmady N. (2021). Curcumin-gold-polyethylene glycol nanoparticles as a nanosensitizer for photothermal and sonodynamic therapies: In vitro and animal model studies. Photodiagnosis Photodyn. Ther. 33, 102139. 10.1016/j.pdpdt.2020.102139 Kessel D. Oleinick N. L. (2009). Initiation of autophagy by photodynamic therapy. Methods Enzymol. 453, 1–16. 10.1016/s0076-6879(08)04001-9 Kessel D. Vicente M. G. Reiners J. J. Jr. (2006). Initiation of apoptosis and autophagy by photodynamic therapy. Autophagy 2 (4), 289–290. 10.4161/auto.2792 Kitanaka C. Kuchino Y. (1999). Caspase-independent programmed cell death with necrotic morphology. Cell Death Differ. 6 (6), 508–515. 10.1038/sj.cdd.4400526 Kocaturk N. M. Akkoc Y. Kig C. Bayraktar O. Gozuacik D. Kutlu O. (2019). Autophagy as a molecular target for cancer treatment. Eur. J. Pharm. Sci. 134, 116–137. 10.1016/j.ejps.2019.04.011 Kondo T. Kano E. (1987). Enhancement of hyperthermic cell killing by non-thermal effect of ultrasound. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 51 (1), 157–166. 10.1080/09553008714550591 Kou J. Y. Li Y. Zhong Z. Y. Jiang Y. Q. Li X. S. Han X. B. (2017). Berberine-sonodynamic therapy induces autophagy and lipid unloading in macrophage. Cell Death Dis. 8 (1), e2558. 10.1038/cddis.2016.354 Kwon S. Ko H. You D. G. Kataoka K. Park J. H. (2019). Nanomedicines for reactive oxygen species mediated approach: An emerging paradigm for cancer treatment. Acc. Chem. Res. 52 (7), 1771–1782. 10.1021/acs.accounts.9b00136 Lee H. O. Mustafa A. Hudes G. R. Kruger W. D. (2015). Hydroxychloroquine destabilizes phospho-S6 in human renal carcinoma cells. PLoS One 10 (7), e0131464. 10.1371/journal.pone.0131464 Levy J. M. M. Towers C. G. Thorburn A. (2017). Targeting autophagy in cancer. Nat. Rev. Cancer 17 (9), 528–542. 10.1038/nrc.2017.53 Li G. Zhong X. Wang X. Gong F. Lei H. Zhou Y. (2022). Titanium carbide nanosheets with defect structure for photothermal-enhanced sonodynamic therapy. Bioact. Mat. 8, 409–419. 10.1016/j.bioactmat.2021.06.021 Li J. Luo Y. Pu K. (2021). Electromagnetic nanomedicines for combinational cancer immunotherapy. Angew. Chem. Int. Ed. Engl. 60 (23), 12682–12705. 10.1002/anie.202008386 Li Q. Liu Q. Wang P. Feng X. Wang H. Wang X. (2014a). The effects of Ce6-mediated sono-photodynamic therapy on cell migration, apoptosis and autophagy in mouse mammary 4T1 cell line. Ultrasonics 54 (4), 981–989. 10.1016/j.ultras.2013.11.009 Li Q. Wang X. Wang P. Zhang K. Wang H. Feng X. (2014b). Efficacy of chlorin e6-mediated sono-photodynamic therapy on 4T1 cells. Cancer biother. Radiopharm. 29 (1), 42–52. 10.1089/cbr.2013.1526 Li X. J. Feng J. Zhang R. Wang J. D. Su T. Tian Z. H. (2016c). Quaternized chitosan/alginate-Fe3O4 magnetic nanoparticles enhance the chemosensitization of multidrug-resistant gastric carcinoma by regulating cell autophagy activity in mice. J. Biomed. Nanotechnol. 12 (5), 948–961. 10.1166/jbn.2016.2232 Li X. Zhang X. Zheng L. Kou J. Zhong Z. Jiang Y. (2016a). Hypericin-mediated sonodynamic therapy induces autophagy and decreases lipids in THP-1 macrophage by promoting ROS-dependent nuclear translocation of TFEB. Cell Death Dis. 7 (12), e2527. 10.1038/cddis.2016.433 Li X. Zhang X. Zheng L. Kou J. Zhong Z. Jiang Y. (2016b). Hypericin-mediated sonodynamic therapy induces autophagy and decreases lipids in THP-1 macrophage by promoting ROS-dependent nuclear translocation of TFEB. Cell Death Dis. 7 (12), e2527. 10.1038/cddis.2016.433 Li Y. Hao L. Liu F. Yin L. Yan S. Zhao H. (2019). Cell penetrating peptide-modified nanoparticles for tumor targeted imaging and synergistic effect of sonodynamic/HIFU therapy. Int. J. Nanomedicine 14, 5875–5894. 10.2147/ijn.s212184 Li Y. Xie J. Um W. You D. G. Kwon S. Zhang L. (2020). Sono/photodynamic nanomedicine‐elicited cancer immunotherapy. Adv. Funct. Mat. 31 (12), 2008061. 10.1002/adfm.202008061 Li Z. Han J. Yu L. Qian X. Xing H. Lin H. (2018). Synergistic sonodynamic/chemotherapeutic suppression of hepatocellular carcinoma by targeted biodegradable mesoporous nanosonosensitizers. Adv. Funct. Mat. 28 (26), 1800145. 10.1002/adfm.201800145 Liang J. L. Luo G. F. Chen W. H. Zhang X. Z. (2021). Recent advances in engineered materials for immunotherapy-involved combination cancer therapy. Adv. Mat. 33 (31), e2007630. 10.1002/adma.202007630 Liang S. Deng X. Ma P. Cheng Z. Lin J. (2020a). Recent advances in nanomaterial-assisted combinational sonodynamic cancer therapy. Adv. Mat. 32, e2003214. 10.1002/adma.202003214 Liang S. Deng X. R. Xu G. Y. Xiao X. Wang M. F. Guo X. S. (2020b). A novel Pt-TiO2 heterostructure with oxygen-deficient layer as bilaterally enhanced sonosensitizer for synergistic chemo-sonodynamic cancer therapy. Adv. Funct. Mat. 30 (13), 1908598. 10.1002/adfm.201908598 Lin X. He T. Tang R. Li Q. Wu N. Zhou Y. (2022). Biomimetic nanoprobe-augmented triple therapy with photothermal, sonodynamic and checkpoint blockade inhibits tumor growth and metastasis. J. Nanobiotechnology 20 (1), 80. 10.1186/s12951-022-01287-y Lin X. H. Qiu Y. Song L. Chen S. Chen X. F. Huang G. M. (2019). Ultrasound activation of liposomes for enhanced ultrasound imaging and synergistic gas and sonodynamic cancer therapy. Nanoscale Horiz. 4 (3), 747–756. 10.1039/c8nh00340h Lin X. Huang R. Huang Y. Wang K. Li H. Bao Y. (2021). Nanosonosensitizer-Augmented sonodynamic therapy combined with checkpoint blockade for cancer immunotherapy. Int. J. Nanomedicine 16, 1889–1899. 10.2147/IJN.S290796 Liu M. Khan A. R. Ji J. Lin G. Zhao X. Zhai G. (2018). Crosslinked self-assembled nanoparticles for chemo-sonodynamic combination therapy favoring antitumor, antimetastasis management and immune responses. J. Control. Release 290, 150–164. 10.1016/j.jconrel.2018.10.007 Liu Q. Sun S. Xiao Y. Qi H. Shang Z. Zhang J. (2003). Study of cell killing and morphology on S180 by ultrasound activating hematoporphyrin derivatives. Sci. China. C Life Sci. 46 (3), 253–262. 10.1360/03yc9027 Liu X. Li W. Geng S. Meng Q. G. Bi Z. G. (2015). Apoptosis induced by sonodynamic therapy in human osteosarcoma cells in vitro . Mol. Med. Rep. 12 (1), 1183–1188. 10.3892/mmr.2015.3479 Liu Y. Wan G. Guo H. Liu Y. Zhou P. Wang H. (2017). A multifunctional nanoparticle system combines sonodynamic therapy and chemotherapy to treat hepatocellular carcinoma. Nano Res. 10 (3), 834–855. 10.1007/s12274-016-1339-8 Liu Y. Wang P. Liu Q. Wang X. (2016). Sinoporphyrin sodium triggered sono-photodynamic effects on breast cancer both in vitro and in vivo . Ultrason. Sonochem. 31, 437–448. 10.1016/j.ultsonch.2016.01.038 Liu Z. Li J. Chen W. Liu L. Yu F. (2020). Light and sound to trigger the pandora's box against breast cancer: A combination strategy of sonodynamic, photodynamic and photothermal therapies. Biomaterials 232, 119685. 10.1016/j.biomaterials.2019.119685 Liu Z. Wang D. Li J. Jiang Y. (2019). Self-assembled peptido-nanomicelles as an engineered formulation for synergy-enhanced combinational SDT, PDT and chemotherapy to nasopharyngeal carcinoma. Chem. Commun. 55 (69), 10226–10229. 10.1039/c9cc05463d Logan K. Foglietta F. Nesbitt H. Sheng Y. McKaig T. Kamila S. (2019). Targeted chemo-sonodynamic therapy treatment of breast tumours using ultrasound responsive microbubbles loaded with paclitaxel, doxorubicin and Rose Bengal. Eur. J. Pharm. Biopharm. 139, 224–231. 10.1016/j.ejpb.2019.04.003 Lu J. He L. Behrends C. Araki M. Araki K. Jun Wang Q. (2014). NRBF2 regulates autophagy and prevents liver injury by modulating Atg14L-linked phosphatidylinositol-3 kinase III activity. Nat. Commun. 5, 3920. 10.1038/ncomms4920 Lv Y. Zheng J. Zhou Q. Jia L. Wang C. Liu N. (2017). Antiproliferative and apoptosis-inducing effect of exo-protoporphyrin IX based sonodynamic therapy on human oral squamous cell carcinoma. Sci. Rep. 7, 40967. 10.1038/srep40967 Mahalingam D. Mita M. Sarantopoulos J. Wood L. Amaravadi R. K. Davis L. E. (2014). Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors. Autophagy 10 (8), 1403–1414. 10.4161/auto.29231 Matsunaga K. Saitoh T. Tabata K. Omori H. Satoh T. Kurotori N. (2009). Two Beclin 1-binding proteins, Atg14L and Rubicon, reciprocally regulate autophagy at different stages. Nat. Cell Biol. 11 (4), 385–396. 10.1038/ncb1846 McHale A. P. Callan J. F. Nomikou N. Fowley C. Callan B. (2016). Sonodynamic therapy: Concept, mechanism and application to cancer treatment. Adv. Exp. Med. Biol. 880, 429–450. 10.1007/978-3-319-22536-4_22 Misik V. Riesz P. (2000). Free radical intermediates in sonodynamic therapy. Ann. N. Y. Acad. Sci. 899, 335–348. 10.1111/j.1749-6632.2000.tb06198.x Mony V. K. Benjamin S. O'Rourke E. J. (2016). A lysosome-centered view of nutrient homeostasis. Autophagy 12 (4), 619–631. 10.1080/15548627.2016.1147671 Nakatogawa H. (2013). Two ubiquitin-like conjugation systems that mediate membrane formation during autophagy. Essays Biochem. 55, 39–50. 10.1042/bse0550039 Nene L. C. Nyokong T. (2021). Photo-sonodynamic combination activity of cationic morpholino-phthalocyanines conjugated to nitrogen and nitrogen-sulfur doped graphene quantum dots against MCF-7 breast cancer cell line in vitro . Photodiagnosis Photodyn. Ther. 36, 102573. 10.1016/j.pdpdt.2021.102573 Nesbitt H. Sheng Y. Kamila S. Logan K. Thomas K. Callan B. (2018). Gemcitabine loaded microbubbles for targeted chemo-sonodynamic therapy of pancreatic cancer. J. Control. Release 279, 8–16. 10.1016/j.jconrel.2018.04.018 Nora Frulio H. T. Deckers R. Deckers R. Lepreux S. Moonen C. Quesson B. (2010). Influence of ultrasound induced cavitation on magnetic resonance imaging contrast in the rat liver in the presence of macromolecular contrast agent. Invest. Radiol. 45 (5), 282–287. 10.1097/RLI.0b013e3181dac2a7 Ohmura T. Fukushima T. Shibaguchi H. Yoshizawa S. Inoue T. Kuroki M. (2011). Sonodynamic therapy with 5-aminolevulinic acid and focused ultrasound for deep-seated intracranial glioma in rat. Anticancer Res. 31 (7), 2527–2533. Orsi A. Razi M. Dooley H. C. Robinson D. Weston A. E. Collinson L. M. (2012). Dynamic and transient interactions of Atg9 with autophagosomes, but not membrane integration, are required for autophagy. Mol. Biol. Cell 23 (10), 1860–1873. 10.1091/mbc.E11-09-0746 Padilla F. Puts R. Vico L. Guignandon A. Raum K. (2016). Stimulation of bone repair with ultrasound. Adv. Exp. Med. Biol. 880, 385–427. 10.1007/978-3-319-22536-4_21 Pan X. Bai L. Wang H. Wu Q. Wang H. Liu S. (2018a). Metal-organic-framework-Derived carbon nanostructure augmented sonodynamic cancer therapy. Adv. Mat. 30 (23), e1800180. 10.1002/adma.201800180 Pan X. Wang H. Wang S. Sun X. Wang L. Wang W. (2018b). Sonodynamic therapy (SDT): A novel strategy for cancer nanotheranostics. Sci. China. Life Sci. 61 (4), 415–426. 10.1007/s11427-017-9262-x Pan X. Wang W. Huang Z. Liu S. Guo J. Zhang F. (2020). MOF-derived double-layer hollow nanoparticles with oxygen generation ability for multimodal imaging-guided sonodynamic therapy. Angew. Chem. Int. Ed. Engl. 59 (32), 13557–13561. 10.1002/anie.202004894 Park J. M. Jung C. H. Seo M. Otto N. M. Grunwald D. Kim K. H. (2016). The ULK1 complex mediates MTORC1 signaling to the autophagy initiation machinery via binding and phosphorylating ATG14. Autophagy 12 (3), 547–564. 10.1080/15548627.2016.1140293 Parzych K. R. Klionsky D. J. (2014). An overview of autophagy: Morphology, mechanism, and regulation. Antioxid. Redox Signal. 20 (3), 460–473. 10.1089/ars.2013.5371 Pelt J. Busatto S. Ferrari M. Thompson E. A. Mody K. Wolfram J. (2018). Chloroquine and nanoparticle drug delivery: A promising combination. Pharmacol. Ther. 191, 43–49. 10.1016/j.pharmthera.2018.06.007 Qian X. Zheng Y. Chen Y. (2016). Micro/nanoparticle-Augmented sonodynamic therapy (SDT): Breaking the depth shallow of photoactivation. Adv. Mat. 28 (37), 8097–8129. 10.1002/adma.201602012 Qu F. Wang P. Zhang K. Shi Y. Li Y. Li C. (2020). Manipulation of Mitophagy by "All-in-One" nanosensitizer augments sonodynamic glioma therapy. Autophagy 16 (8), 1413–1435. 10.1080/15548627.2019.1687210 Rangwala R. Chang Y. C. Hu J. Algazy K. M. Evans T. L. Fecher L. A. (2014). Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma. Autophagy 10 (8), 1391–1402. 10.4161/auto.29119 Ravikumar B. Moreau K. Jahreiss L. Puri C. Rubinsztein D. C. (2010). Plasma membrane contributes to the formation of pre-autophagosomal structures. Nat. Cell Biol. 12 (8), 747–757. 10.1038/ncb2078 Ren Q. Yu N. Wang L. Wen M. Geng P. Jiang Q. (2022). Nanoarchitectonics with metal-organic frameworks and platinum nanozymes with improved oxygen evolution for enhanced sonodynamic/chemo-therapy. J. Colloid Interface Sci. 614, 147–159. 10.1016/j.jcis.2022.01.050 Rengeng L. Qianyu Z. Yuehong L. Zhongzhong P. Libo L. (2017). Sonodynamic therapy, a treatment developing from photodynamic therapy. Photodiagnosis Photodyn. Ther. 19, 159–166. 10.1016/j.pdpdt.2017.06.003 Rkein A. M. Ozog D. M. (2014). Photodynamic therapy. Dermatol. Clin. 32 (3), 415–425. 10.1016/j.det.2014.03.009 Rosenfeld M. R. Ye X. Supko J. G. Desideri S. Grossman S. A. Brem S. (2014). A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy 10 (8), 1359–1368. 10.4161/auto.28984 Satoo K. Noda N. N. Kumeta H. Fujioka Y. Mizushima N. Ohsumi Y. (2009). The structure of Atg4B-LC3 complex reveals the mechanism of LC3 processing and delipidation during autophagy. Embo J. 28 (9), 1341–1350. 10.1038/emboj.2009.80 Shanei A. Sazgarnia A. Tayyebi Meibodi N. Eshghi H. Hassanzadeh-Khayyat M. Esmaily H. (2012). Sonodynamic therapy using protoporphyrin IX conjugated to gold nanoparticles: An in vivo study on a colon tumor model. Iran. J. Basic Med. Sci. 15 (2), 759–767. Shen Q. Shi Y. Liu J. Su H. Huang J. Zhang Y. (2021). Acetylation of STX17 (syntaxin 17) controls autophagosome maturation. Autophagy 17 (5), 1157–1169. 10.1080/15548627.2020.1752471 Shen S. Wu L. Liu J. Xie M. Shen H. Qi X. (2015). Core-shell structured Fe3O4@TiO2-doxorubicin nanoparticles for targeted chemo-sonodynamic therapy of cancer. Int. J. Pharm. 486 (1-2), 380–388. 10.1016/j.ijpharm.2015.03.070 Shi J. Chen Z. Wang B. Wang L. Lu T. Zhang Z. (2015). Reactive oxygen species-manipulated drug release from a smart envelope-type mesoporous titanium nanovehicle for tumor sonodynamic-chemotherapy. ACS Appl. Mat. Interfaces 7 (51), 28554–28565. 10.1021/acsami.5b09937 Shi T. T. Yu X. X. Yan L. J. Xiao H. T. (2017). Research progress of hydroxychloroquine and autophagy inhibitors on cancer. Cancer Chemother. Pharmacol. 79 (2), 287–294. 10.1007/s00280-016-3197-1 Song L. Huang Y. Hou X. Yang Y. Kala S. Qiu Z. (2018). PINK1/Parkin-Mediated mitophagy promotes resistance to sonodynamic therapy. Cell. Physiol. biochem. 49 (5), 1825–1839. 10.1159/000493629 Song Shen X. G. Wu L. Wang M. Wang b. X. Wang X. Kong F. (2014). Fenfen Kong, Haijun Shen, Meng Xie, Yanru Ge and Yi JinDual-core@shell-structured Fe3O4–NaYF4@TiO2 nanocomposites as a magnetic targeting drug carrier for bioimaging and combined chemosonodynamic therapy. J. Mat. Chem. B 2, 5775–5784. 10.1039/C4TB00841C Su X. Wang P. Yang S. Zhang K. Liu Q. Wang X. (2015). Sonodynamic therapy induces the interplay between apoptosis and autophagy in K562 cells through ROS. Int. J. Biochem. Cell Biol. 60, 82–92. 10.1016/j.biocel.2014.12.023 Sui X. Chen R. Wang Z. Huang Z. Kong N. Zhang M. (2013). Autophagy and chemotherapy resistance: A promising therapeutic target for cancer treatment. Cell Death Dis. 4 (10), e838. 10.1038/cddis.2013.350 Suslick K. S. Doktycz S. J. Flint E. B. (1990). On the origin of sonoluminescence and sonochemistry. Ultrasonics 28 (5), 280–290. 10.1016/0041-624X(90)90033-K Suslick K. S. (1990). Sonochemistry., Sonochemistry. Sci. 247(4949), 1439–1445. doi: doi:10.1126/science.247.4949.1439 Sviridov A. P. Osminkina L. A. Kharin A. Y. Gongalsky M. B. Kargina J. V. Kudryavtsev A. A. (2017). Cytotoxicity control of silicon nanoparticles by biopolymer coating and ultrasound irradiation for cancer theranostic applications. Nanotechnology 28 (10), 105102. 10.1088/1361-6528/aa5b7c Takahashi Y. Meyerkord C. L. Hori T. Runkle K. Fox T. E. Kester M. (2011). Bif-1 regulates Atg9 trafficking by mediating the fission of Golgi membranes during autophagy. Autophagy 7 (1), 61–73. 10.4161/auto.7.1.14015 Tan X. Huang J. Wang Y. He S. Jia L. Zhu Y. (2021). Transformable nanosensitizer with tumor microenvironment-activated sonodynamic process and calcium release for enhanced cancer immunotherapy. Angew. Chem. Int. Ed. Engl. 60 (25), 14051–14059. 10.1002/anie.202102703 Tanida I. (2011). Autophagosome formation and molecular mechanism of autophagy. Antioxid. Redox Signal. 14 (11), 2201–2214. 10.1089/ars.2010.3482 Tsuboyama K. Koyama-Honda I. Sakamaki Y. Koike M. Morishita H. Mizushima N. (2016). The ATG conjugation systems are important for degradation of the inner autophagosomal membrane. Science 354 (6315), 1036–1041. 10.1126/science.aaf6136 Vogl D. T. Stadtmauer E. A. Tan K. S. Heitjan D. F. Davis L. E. Pontiggia L. (2014). Combined autophagy and proteasome inhibition: A phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma. Autophagy 10 (8), 1380–1390. 10.4161/auto.29264 Wan G. Chen X. Wang H. Hou S. Wang Q. Cheng Y. (2021). Gene augmented nuclear-targeting sonodynamic therapy via Nrf2 pathway-based redox balance adjustment boosts peptide-based anti-PD-L1 therapy on colorectal cancer. J. Nanobiotechnology 19 (1), 347. 10.1186/s12951-021-01094-x Wan G. Liu Y. Shi S. Chen B. Wang Y. Wang H. (2016a). Hematoporphyrin and doxorubicin co-loaded nanomicelles for the reversal of drug resistance in human breast cancer cells by combining sonodynamic therapy and chemotherapy. RSC Adv. 6 (102), 100361–100372. 10.1039/c6ra22724d Wan G. Y. Liu Y. Chen B. W. Liu Y. Y. Wang Y. S. Zhang N. (2016b). Recent advances of sonodynamic therapy in cancer treatment. Cancer Biol. Med. 13 (3), 325–338. 10.20892/j.issn.2095-3941.2016.0068 Wang H. Wang X. Wang P. Zhang K. Yang S. Liu Q. (2013a). Ultrasound enhances the efficacy of chlorin E6-mediated photodynamic therapy in MDA-MB-231 cells. Ultrasound Med. Biol. 39 (9), 1713–1724. 10.1016/j.ultrasmedbio.2013.03.017 Wang L. Li G. Z. Cao L. Dong Y. Wang Y. Wang S. S. (2021a). An ultrasound-driven immune-boosting molecular machine for systemic tumor suppression. Sci. Adv. 7 (43), eabj4796. 10.1126/sciadv.abj4796 Wang P. Li C. Wang X. Xiong W. Feng X. Liu Q. (2015a). Anti-metastatic and pro-apoptotic effects elicited by combination photodynamic therapy with sonodynamic therapy on breast cancer both in vitro and in vivo . Ultrason. Sonochem. 23, 116–127. 10.1016/j.ultsonch.2014.10.027 Wang P. Wang X. Ma L. Sahi S. Li L. Wang X. B. (2018). Nanosonosensitization by using copper-cysteamine nanoparticles augmented sonodynamic cancer treatment. Part. Part. Syst. Charact. 35 (4), 1700378. 10.1002/ppsc.201700378 Wang X. Jia Y. Su X. Wang P. Zhang K. Feng X. (2015b). Combination of protoporphyrin IX-mediated sonodynamic treatment with doxorubicin synergistically induced apoptotic cell death of a multidrug-resistant leukemia K562/DOX cell line. Ultrasound Med. Biol. 41 (10), 2731–2739. 10.1016/j.ultrasmedbio.2015.06.001 Wang X. Liu Q. Wang Z. Wang P. Zhao P. Zhao X. (2010a). Role of autophagy in sonodynamic therapy-induced cytotoxicity in S180 cells. Ultrasound Med. Biol. 36 (11), 1933–1946. 10.1016/j.ultrasmedbio.2010.06.022 Wang X. Liu Q. Wang Z. Wang P. Zhao P. Zhao X. (2010b). Role of autophagy in sonodynamic therapy-induced cytotoxicity in s180 cells. Ultrasound Med. Biol. 36 (11), 1933–1946. 10.1016/j.ultrasmedbio.2010.06.022 Wang X. Wang P. Zhang K. Su X. Hou J. Liu Q. (2013b). Initiation of autophagy and apoptosis by sonodynamic therapy in murine leukemia L1210 cells. Toxicol. Vitro 27 (4), 1247–1259. 10.1016/j.tiv.2012.12.023 Wang X. Wang X. Yue Q. Xu H. Zhong X. Sun L. (2021b). Liquid exfoliation of TiN nanodots as novel sonosensitizers for photothermal-enhanced sonodynamic therapy against cancer. Nano Today 39, 101170. 10.1016/j.nantod.2021.101170 Wang X. Wang Y. Wang P. Cheng X. Liu Q. (2011). Sonodynamically induced anti-tumor effect with protoporphyrin IX on hepatoma-22 solid tumor. Ultrasonics 51 (5), 539–546. 10.1016/j.ultras.2010.12.001 Wang Z. Bai J. Li F. Du Y. Wen S. Hu K. (2003). Study of a "biological focal region" of high-intensity focused ultrasound. Ultrasound Med. Biol. 29 (5), 749–754. 10.1016/s0301-5629(02)00785-8 Wang Z. Liu C. Zhao Y. Hu M. Ma D. Zhang P. (2019). Photomagnetic nanoparticles in dual-modality imaging and photo-sonodynamic activity against bacteria. Chem. Eng. J. 356, 811–818. 10.1016/j.cej.2018.09.077 White E. Mehnert J. M. Chan C. S. (2015). Autophagy, metabolism, and cancer. Clin. Cancer Res. 21 (22), 5037–5046. 10.1158/1078-0432.ccr-15-0490 Wu P. Sun Y. Dong W. Zhou H. Guo S. Zhang L. (2019). Enhanced anti-tumor efficacy of hyaluronic acid modified nanocomposites combined with sonochemotherapy against subcutaneous and metastatic breast tumors. Nanoscale 11 (24), 11470–11483. 10.1039/c9nr01691k Wu Y. Liu X. Qin Z. Hu L. Wang X. (2018). Low-frequency ultrasound enhances chemotherapy sensitivity and induces autophagy in PTX-resistant PC-3 cells via the endoplasmic reticulum stress-mediated PI3K/Akt/mTOR signaling pathway. Onco. Targets. Ther. 11, 5621–5630. 10.2147/ott.s176744 Xiao Z. Zhuang B. Zhang G. Li M. Jin Y. (2021). Pulmonary delivery of cationic liposomal hydroxycamptothecin and 5-aminolevulinic acid for chemo-sonodynamic therapy of metastatic lung cancer. Int. J. Pharm. 601, 120572. 10.1016/j.ijpharm.2021.120572 Xiaohuai W. Lewis T. J. Mitchell D. (2008). The tumoricidal effect of sonodynamic therapy (SDT) on S-180 sarcoma in mice. Integr. Cancer Ther. 7 (2), 96–102. 10.1177/1534735408319065 Xiong J. Jiang B. Luo Y. Zou J. Gao X. Xu D. (2020). Multifunctional nanoparticles encapsulating Astragalus polysaccharide and gold nanorods in combination with focused ultrasound for the treatment of breast cancer. Int. J. Nanomedicine 15, 4151–4169. 10.2147/IJN.S246447 Xu F. Hu M. Liu C. Choi S. K. (2017). Yolk-structured multifunctional up-conversion nanoparticles for synergistic photodynamic–sonodynamic antibacterial resistance therapy. Biomater. Sci. 5 (4), 678–685. 10.1039/c7bm00030h Xu H. Yu N. Zhang J. Wang Z. Geng P. Wen M. (2020a). Biocompatible Fe-Hematoporphyrin coordination nanoplatforms with efficient sonodynamic-chemo effects on deep-seated tumors. Biomaterials 257, 120239. 10.1016/j.biomaterials.2020.120239 Xu P. Yao J. Li Z. Wang M. Zhou L. Zhong G. (2020b). Therapeutic effect of doxorubicin-chlorin E6-loaded mesoporous silica nanoparticles combined with ultrasound on triple-negative breast cancer. Int. J. Nanomedicine 15, 2659–2668. 10.2147/ijn.s243037 Xue L. Y. Chiu S. M. Azizuddin K. Joseph S. Oleinick N. L. (2007). The death of human cancer cells following photodynamic therapy: Apoptosis competence is necessary for bcl-2 protection but not for induction of autophagy. Photochem. Photobiol. 83 (5), 1016–1023. 10.1111/j.1751-1097.2007.00159.x Yang Z. Tao D. Zhong W. Liu Z. Feng L. Chen M. (2022). Perfluorocarbon loaded fluorinated covalent organic polymers with effective sonosensitization and tumor hypoxia relief enable synergistic sonodynamic-immunotherapy. Biomaterials 280, 121250. 10.1016/j.biomaterials.2021.121250 Ye J. Fu Q. Liu L. Chen L. Zhang X. Li Q. (2021). Ultrasound-propelled Janus Au NR-mSiO2 nanomotor for NIR-II photoacoustic imaging guided sonodynamic-gas therapy of large tumors. Sci. China Chem. 64 (12), 2218–2229. 10.1007/s11426-021-1070-6 Yim W. W. Mizushima N. (2020). Lysosome biology in autophagy. Cell Discov. 6, 6. 10.1038/s41421-020-0141-7 Yin H. Chang N. Xu S. Wan M. (2016). Sonoluminescence characterization of inertial cavitation inside a BSA phantom treated by pulsed HIFU. Ultrason. Sonochem. 32, 158–164. 10.1016/j.ultsonch.2016.02.025 Yin Y. Jiang X. Sun L. Li H. Su C. Zhang Y. (2021). Continuous inertial cavitation evokes massive ROS for reinforcing sonodynamic therapy and immunogenic cell death against breast carcinoma. Nano Today 36, 101009. 10.1016/j.nantod.2020.101009 Yu Z. Cao W. Han C. Wang Z. Qiu Y. Wang J. (2022). Biomimetic metal-organic framework nanoparticles for synergistic combining of SDT-chemotherapy induce pyroptosis in gastric cancer. Front. Bioeng. Biotechnol. 10, 796820. 10.3389/fbioe.2022.796820 Yuan F. Yang C. Zhong P. (2015). Cell membrane deformation and bioeffects produced by tandem bubble-induced jetting flow. Proc. Natl. Acad. Sci. U. S. A. 112 (51), E7039–E7047. 10.1073/pnas.1518679112 Yuan Y. G. Gurunathan S. (2017). Combination of graphene oxide-silver nanoparticle nanocomposites and cisplatin enhances apoptosis and autophagy in human cervical cancer cells. Int. J. Nanomedicine 12, 6537–6558. 10.2147/ijn.s125281 Yue W. W. Chen L. Yu L. D. Zhou B. G. Yin H. H. Ren W. W. (2019). Checkpoint blockade and nanosonosensitizer- augmented noninvasive sonodynamic therapy combination reduces tumour growth and metastases in mice. Nat. Com. 10. 10.1038/s41467-019-09760-3 Yumita N. Nishigaki R. Umemura K. Umemura S. (1989). Hematoporphyrin as a sensitizer of cell-damaging effect of ultrasound. Jpn. J. Cancer Res. 80 (3), 219–222. 10.1111/j.1349-7006.1989.tb02295.x Yumita N. Okuyama N. Sasaki K. Umemura S. (2007). Sonodynamic therapy on chemically induced mammary tumor: Pharmacokinetics, tissue distribution and sonodynamically induced antitumor effect of gallium-porphyrin complex ATX-70. Cancer Chemother. Pharmacol. 60 (6), 891–897. 10.1007/s00280-007-0436-5 Yumita N. Okuyama N. Sasaki K. Umemura S. (2004). Sonodynamic therapy on chemically induced mammary tumor: Pharmacokinetics, tissue distribution and sonodynamically induced antitumor effect of porfimer sodium. Cancer Sci. 95 (9), 765–769. 10.1111/j.1349-7006.2004.tb03259.x Yun C. W. Lee S. H. (2018). The roles of autophagy in cancer. Int. J. Mol. Sci. 19 (11), E3466. 10.3390/ijms19113466 Zachari M. Ganley I. G. (2017). The mammalian ULK1 complex and autophagy initiation. Essays Biochem. 61 (6), 585–596. 10.1042/ebc20170021 Zeng X. Zhao H. Li Y. Fan J. Sun Y. Wang S. (2015). Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia. Autophagy 11 (2), 355–372. 10.4161/15548627.2014.994368 Zhang H. Ren Y. Cao F. Chen J. Chen C. Chang J. (2019a). In situ autophagy disruption generator for cancer theranostics. ACS Appl. Mat. Interfaces 11 (33), 29641–29654. 10.1021/acsami.9b10578 Zhang J. Shi C. Shan F. Shi N. Ye W. Zhuo Y. (2021a). From biology to biology: Hematoporphyrin-melanin nanoconjugates with synergistic sonodynamic-photothermal effects on malignant tumors. Chem. Eng. J. 408, 127282. 10.1016/j.cej.2020.127282 Zhang L. Yi H. Song J. Huang J. Yang K. Tan B. (2019b). Mitochondria-targeted and ultrasound-activated nanodroplets for enhanced deep-penetration sonodynamic cancer therapy. ACS Appl. Mat. Interfaces 11 (9), 9355–9366. 10.1021/acsami.8b21968 Zhang Q. Wang W. Shen H. Tao H. Wu Y. Ma L. (2021b). Low-intensity focused ultrasound-augmented multifunctional nanoparticles for integrating ultrasound imaging and synergistic therapy of metastatic breast cancer. Nanoscale Res. Lett. 16 (1), 73. 10.1186/s11671-021-03532-z Zhang R. Y. Cheng K. Xuan Y. Yang X. Q. An J. Hu Y. G. (2021c). A pH/ultrasonic dual-response step-targeting enterosoluble granule for combined sonodynamic-chemotherapy guided via gastrointestinal tract imaging in orthotopic colorectal cancer. Nanoscale 13 (7), 4278–4294. 10.1039/d0nr08100k Zhang Y. Kang S. Lin H. Chen M. Li Y. Cui L. (2022). Regulation of zeolite-derived upconversion photocatalytic system for near infrared light/ultrasound dual-triggered multimodal melanoma therapy under a boosted hypoxia relief tumor microenvironment via autophagy. Chem. Eng. J. 429, 132484. 10.1016/j.cej.2021.132484 Zhao Y. G. Codogno P. Zhang H. (2021). Machinery, regulation and pathophysiological implications of autophagosome maturation. Nat. Rev. Mol. Cell Biol. 22 (11), 733–750. 10.1038/s41580-021-00392-4 Zhao Y. Hu M. Zhang Y. Liu J. Liu C. Choi S. K. (2020). Multifunctional therapeutic strategy of Ag-synergized dual-modality upconversion nanoparticles to achieve the rapid and sustained cidality of methicillin-resistant Staphylococcus aureus . Chem. Eng. J. 385, 123980. 10.1016/j.cej.2019.123980 Zheng Y. Li Z. Yang Y. Shi H. Chen H. Gao Y. (2021a). A nanosensitizer self-assembled from oleanolic acid and chlorin e6 for synergistic chemo/sono-photodynamic cancer therapy. Phytomedicine. 93, 153788. 10.1016/j.phymed.2021.153788 Zheng Y. Liu Y. Wei F. Xiao H. Mou J. Wu H. (2021b). Functionalized g-C3N4 nanosheets for potential use in magnetic resonance imaging-guided sonodynamic and nitric oxide combination therapy. Acta Biomater. 121, 592–604. 10.1016/j.actbio.2020.12.011 Zhong X. Y. Wang X. W. Cheng L. Tang Y. A. Zhan G. T. Gong F. (2020). GSH-depleted PtCu3 nanocages for chemodynamic- enhanced sonodynamic cancer therapy. Adv. Funct. Mat. 30 (4), 1907954. 10.1002/adfm.201907954 Zhou L. Huo M. Qian X. Ding L. Yu L. Feng W. (2021). Autophagy blockade synergistically enhances nanosonosensitizer-enabled sonodynamic cancer nanotherapeutics. J. Nanobiotechnology 19 (1), 112. 10.1186/s12951-021-00855-y Zhu J. Ouyang A. He J. Xie J. Banerjee S. Zhang Q. (2022). An ultrasound activated cyanine-rhenium(I) complex for sonodynamic and gas synergistic therapy. Chem. Commun. 58 (20), 3314–3317. 10.1039/d1cc06769a Zhu P. Chen Y. Shi J. (2020a). Piezocatalytic tumor therapy by ultrasound-triggered and BaTiO(3) -mediated piezoelectricity. Adv. Mat. 32 (29), e2001976. 10.1002/adma.202001976 Zhu W. Chen Q. Jin Q. Chao Y. Sun L. Han X. (2020b). Sonodynamic therapy with immune modulatable two-dimensional coordination nanosheets for enhanced anti-tumor immunotherapy. Nano Res. 14 (1), 212–221. 10.1007/s12274-020-3070-8 Zou W. Hao J. Wu J. Cai X. Hu B. Wang Z. (2021). Biodegradable reduce expenditure bioreactor for augmented sonodynamic therapy via regulating tumor hypoxia and inducing pro-death autophagy. J. Nanobiotechnology 19 (1), 418. 10.1186/s12951-021-01166-y Zuo S. Zhang Y. Wang Z. Wang J. (2022). Mitochondria-targeted mesoporous titanium dioxide nanoplatform for synergistic nitric oxide gas-sonodynamic therapy of breast cancer. Int. J. Nanomedicine 17, 989–1002. 10.2147/IJN.S348618